Author: "Nucci, M." / Publication Type: Electronic Resources - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Nucci, M."' showing total 66 results

Start Over Author "Nucci, M." Publication Type Electronic Resources

66 results on '"Nucci, M."'

1. Minimally superintegrable systems in flat three-dimensional space are also linearizable

Author: Nucci, M. C., Campoamor Stursberg, Otto-Rudwig, Nucci, M. C., and Campoamor Stursberg, Otto-Rudwig
Abstract: This article may be downloaded for personal use only. Any other use requires prior permission of the author and AIP Publishing. This article appeared in M. C. Nucci and R. Campoamor-Stursberg. Minimally superintegrable systems in flat three-dimensional space are also linearizable. J Math Phys. 63 (2022), no. 12, 123510, and may be found at https://doi.org/10.1063/5.0086431., It is shown that all minimally superintegrable Hamiltonian systems in a three-dimensional flat space derived in the work of Evans [Phys. Rev. A 41, 5666–5676 (1990)] possess hidden symmetries leading to their linearization., Ministerio de Ciencia e Innovación, Depto. de Álgebra, Geometría y Topología, Fac. de Ciencias Matemáticas, Instituto de Matemática Interdisciplinar (IMI), TRUE, pub
Published: 2024

2. Testing and assessment in psychology. A survey on Italian psychologists at the time of COVID-19 pandemic

Author: Bobbio, A, Nucci, M, Daini, R, Aschieri, F, Traficante, D, Laghi, F, Parolin, L, Lis, A, Bobbio, Andrea, Nucci, Massimo, Daini, Roberta, Aschieri, Filippo, Traficante, Daniela, Laghi, Fiorenzo, Parolin, Laura, Lis, Adriana, Bobbio, A, Nucci, M, Daini, R, Aschieri, F, Traficante, D, Laghi, F, Parolin, L, Lis, A, Bobbio, Andrea, Nucci, Massimo, Daini, Roberta, Aschieri, Filippo, Traficante, Daniela, Laghi, Fiorenzo, Parolin, Laura, and Lis, Adriana
Published: 2024

3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author: Salmanton-Garcia, J., Marchesi, F., Farina, F., Weinbergerova, B., Itri, F., Davila-Valls, J., Martin-Perez, S., Glenthoj, A., Hersby, D. S., Gomes da Silva, M., Nunes Rodrigues, R., Lopez-Garcia, A., Cordoba, R., Bilgin, Y. M., Falces-Romero, I., El-Ashwah, S., Emarah, Z., Besson, C., Kohn, M., Van Doesum, J., Ammatuna, E., Marchetti, M., Labrador, J., Zambrotta, G. P. M., Verga, L., Jaksic, O., Nucci, M., Piukovics, K., Cabirta-Touzon, A., Jimenez, M., Arellano, E., Espigado, I., Blennow, O., Nordlander, A., Meers, S., van Praet, J., Aiello, T. F., Garcia-Vidal, C., Fracchiolla, N., Sciume, M., Seval, G. C., Zak, P., Buquicchio, C., Tascini, C., Grafe, S. K., Schonlein, M., Adzic-Vukicevic, T., Bonuomo, V., Cattaneo, C., Nizamuddin, S., Cernan, M., Plantefeve, G., Prin, R., Szotkovski, T., Collins, G. P., Dargenio, M., Petzer, V., Wolf, D., Colovic, N., Prezioso, L., Valkovic, T., Passamonti, F., Mendez, G. -A., Sili, U., Vena, A., Bavastro, M., Limongelli, A., Duarte, R. F., Ledoux, M. -P., Cvetanoski, M., Stojanoski, Z., Machado, M., Batinic, J., Magliano, G., Biernat, M. M., Pantic, N., Poulsen, C. B., Cuccaro, A., Del Principe, M. I., Kulasekararaj, A., Ormazabal-Velez, I., Busca, A., Demirkan, F., Ijaz, M., Klimko, N., Stoma, I., Khostelidi, S., Fernandez, N., Omrani, A. S., Bergantim, R., De Jonge, N., Fouquet, G., Navratil, M., Abu-Zeinah, G., Samarkos, M., Maertens, J., De Ramon, C., Guidetti, A., Magyari, F., Gonzalez-Lopez, T. J., Lahmer, T., Finizio, O., Ali, N., Pinczes, L. I., Lavilla-Rubira, E., Romano, A., Merelli, M., Delia, M., Calbacho, M., Meletiadis, J., Antic, D., Hernandez-Rivas, J. -A., Marques de Almeida, J., Al-Khabori, M., Hoenigl, M., Tisi, M. C., Khanna, N., Barac, A., Eisa, N., Di Blasi, R., Lievin, R., Miranda-Castillo, C., Bahr, N. C., Lamure, S., Papa, M. V., Yahya, A., Aujayeb, A., Novak, J., Erben, N., Fernandez-Galan, M., Ribera-Santa Susana, J. -M., Rinaldi, I., Fazzi, R., Piedimonte, M., Dulery, R., Gonzaga, Y., Soto-Silva, A., Sapienza, G., Serris, A., Drgona, Groh, A., Serrano, L., Gavriilaki, E., Tragiannidis, A., Prattes, J., Coppola, N., Otasevic, V., Mladenovic, M., Mitrovic, M., Miskovic, B., Jindra, P., Zompi, S., Sacchi, M. V., Krekeler, C., Infante, M. S., Garcia-Bordallo, D., Colak, G. M., Mayer, J., Nygaard, M., Hanakova, M., Racil, Z., Bonanni, Matteo, Koehler, P., Rahimli, L., Cornely, O. A., Pagano, Livio, Martin-Vallejo, F. J., Zdziarski, P., Zarrinfer, H., Wittig, J., Win, S., Wai-Man, V., Visek, B., Vinh, D. C., Vehreschild, M., Varricchio, G., Tsirigotis, P., Torres-Tienza, A., Tanase, A. D., Tafuri, A., Stamouli, M., Sramek, J., Soussain, C., Shirinova, A., Schubert, J., Schalk, E., Salehi, M. R., Saleh, M., Rosati, G., Roldan, E., Reizine, F., Rego, M., Regalado-Artamendi, I., Popova, M., Pinto, F., Philippe, L., Orth, H. M., Ommen, H. -B., Obr, A., Nunez-Martin-Buitrago, L., Noel, N., Neuhann, J., Nadali, G., Nacov, J. A., Munhoz Alburquerque, A. M., Mitra, M. E., Mikulska, M., Mellinghoff, S., Mechtel, B., Martin-Gonzalez, J. -A., Malak, S., Loureiro-Amigo, J., Lorenzo De La Pena, L., Liberti, G., Landau, M., Lacej, I., Kolditz, M., Kho, C. S., Khedr, R. A., Karthaus, M., Karlsson, L. K., Jimenez-Lorenzo, M. -J., Izuzquiza, M., Hoell-Neugebauer, B., Herbrecht, R., Heath, C. H., Guolo, F., Grothe, J., Giordano, A., Gerasymchuk, S., Garcia-Sanz, R., Garcia-Pouton, N., Funke, V. A. M., Fung, M., Flasshove, C., Fianchi, Luana, Essame, J., Egger, M., Drenou, B., Dragonetti, G., Desole, M., Della Pepa, R., Deau Fischer, B., De Kort, E., De Cabo, E., Danion, F., Daguindau, E., Cushion, T., Cremer, L., Criscuolo, Marianna, Cordini, G., Cingolani, Antonella, Ciceri, F., Chowdhury, F. R., Chelysheva, E., Chauchet, A., Chai, L. Y. A., Ceesay, M. M., Busch, E., Brehon, M., Borducchi, D. M. M., Booth, S., Bologna, S., Berg Venemyr, C., Bailen-Almorox, R., Antoniadou, A., Anastasopoulou, A. N., Altuntas, F., Bonanni M., Pagano L. (ORCID:0000-0001-8287-928X), Fianchi L., Criscuolo M., Cingolani A. (ORCID:0000-0002-3793-2755), Salmanton-Garcia, J., Marchesi, F., Farina, F., Weinbergerova, B., Itri, F., Davila-Valls, J., Martin-Perez, S., Glenthoj, A., Hersby, D. S., Gomes da Silva, M., Nunes Rodrigues, R., Lopez-Garcia, A., Cordoba, R., Bilgin, Y. M., Falces-Romero, I., El-Ashwah, S., Emarah, Z., Besson, C., Kohn, M., Van Doesum, J., Ammatuna, E., Marchetti, M., Labrador, J., Zambrotta, G. P. M., Verga, L., Jaksic, O., Nucci, M., Piukovics, K., Cabirta-Touzon, A., Jimenez, M., Arellano, E., Espigado, I., Blennow, O., Nordlander, A., Meers, S., van Praet, J., Aiello, T. F., Garcia-Vidal, C., Fracchiolla, N., Sciume, M., Seval, G. C., Zak, P., Buquicchio, C., Tascini, C., Grafe, S. K., Schonlein, M., Adzic-Vukicevic, T., Bonuomo, V., Cattaneo, C., Nizamuddin, S., Cernan, M., Plantefeve, G., Prin, R., Szotkovski, T., Collins, G. P., Dargenio, M., Petzer, V., Wolf, D., Colovic, N., Prezioso, L., Valkovic, T., Passamonti, F., Mendez, G. -A., Sili, U., Vena, A., Bavastro, M., Limongelli, A., Duarte, R. F., Ledoux, M. -P., Cvetanoski, M., Stojanoski, Z., Machado, M., Batinic, J., Magliano, G., Biernat, M. M., Pantic, N., Poulsen, C. B., Cuccaro, A., Del Principe, M. I., Kulasekararaj, A., Ormazabal-Velez, I., Busca, A., Demirkan, F., Ijaz, M., Klimko, N., Stoma, I., Khostelidi, S., Fernandez, N., Omrani, A. S., Bergantim, R., De Jonge, N., Fouquet, G., Navratil, M., Abu-Zeinah, G., Samarkos, M., Maertens, J., De Ramon, C., Guidetti, A., Magyari, F., Gonzalez-Lopez, T. J., Lahmer, T., Finizio, O., Ali, N., Pinczes, L. I., Lavilla-Rubira, E., Romano, A., Merelli, M., Delia, M., Calbacho, M., Meletiadis, J., Antic, D., Hernandez-Rivas, J. -A., Marques de Almeida, J., Al-Khabori, M., Hoenigl, M., Tisi, M. C., Khanna, N., Barac, A., Eisa, N., Di Blasi, R., Lievin, R., Miranda-Castillo, C., Bahr, N. C., Lamure, S., Papa, M. V., Yahya, A., Aujayeb, A., Novak, J., Erben, N., Fernandez-Galan, M., Ribera-Santa Susana, J. -M., Rinaldi, I., Fazzi, R., Piedimonte, M., Dulery, R., Gonzaga, Y., Soto-Silva, A., Sapienza, G., Serris, A., Drgona, Groh, A., Serrano, L., Gavriilaki, E., Tragiannidis, A., Prattes, J., Coppola, N., Otasevic, V., Mladenovic, M., Mitrovic, M., Miskovic, B., Jindra, P., Zompi, S., Sacchi, M. V., Krekeler, C., Infante, M. S., Garcia-Bordallo, D., Colak, G. M., Mayer, J., Nygaard, M., Hanakova, M., Racil, Z., Bonanni, Matteo, Koehler, P., Rahimli, L., Cornely, O. A., Pagano, Livio, Martin-Vallejo, F. J., Zdziarski, P., Zarrinfer, H., Wittig, J., Win, S., Wai-Man, V., Visek, B., Vinh, D. C., Vehreschild, M., Varricchio, G., Tsirigotis, P., Torres-Tienza, A., Tanase, A. D., Tafuri, A., Stamouli, M., Sramek, J., Soussain, C., Shirinova, A., Schubert, J., Schalk, E., Salehi, M. R., Saleh, M., Rosati, G., Roldan, E., Reizine, F., Rego, M., Regalado-Artamendi, I., Popova, M., Pinto, F., Philippe, L., Orth, H. M., Ommen, H. -B., Obr, A., Nunez-Martin-Buitrago, L., Noel, N., Neuhann, J., Nadali, G., Nacov, J. A., Munhoz Alburquerque, A. M., Mitra, M. E., Mikulska, M., Mellinghoff, S., Mechtel, B., Martin-Gonzalez, J. -A., Malak, S., Loureiro-Amigo, J., Lorenzo De La Pena, L., Liberti, G., Landau, M., Lacej, I., Kolditz, M., Kho, C. S., Khedr, R. A., Karthaus, M., Karlsson, L. K., Jimenez-Lorenzo, M. -J., Izuzquiza, M., Hoell-Neugebauer, B., Herbrecht, R., Heath, C. H., Guolo, F., Grothe, J., Giordano, A., Gerasymchuk, S., Garcia-Sanz, R., Garcia-Pouton, N., Funke, V. A. M., Fung, M., Flasshove, C., Fianchi, Luana, Essame, J., Egger, M., Drenou, B., Dragonetti, G., Desole, M., Della Pepa, R., Deau Fischer, B., De Kort, E., De Cabo, E., Danion, F., Daguindau, E., Cushion, T., Cremer, L., Criscuolo, Marianna, Cordini, G., Cingolani, Antonella, Ciceri, F., Chowdhury, F. R., Chelysheva, E., Chauchet, A., Chai, L. Y. A., Ceesay, M. M., Busch, E., Brehon, M., Borducchi, D. M. M., Booth, S., Bologna, S., Berg Venemyr, C., Bailen-Almorox, R., Antoniadou, A., Anastasopoulou, A. N., Altuntas, F., Bonanni M., Pagano L. (ORCID:0000-0001-8287-928X), Fianchi L., Criscuolo M., and Cingolani A. (ORCID:0000-0002-3793-2755)
Abstract: Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. Methods: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Findings: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. Interpretation: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe
Published: 2024

4. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

Author: Musto, P., Salmanton-Garcia, J., Sgherza, N., Bergantim, R., Farina, F., Glenthoj, A., Cengiz Seval, G., Weinbergerova, B., Bonuomo, V., Bilgin, Y. M., van Doesum, J., Jaksic, O., Visek, B., Falces-Romero, I., Marchetti, M., Davila-Valls, J., Martin-Perez, S., Nucci, M., Lopez-Garcia, A., Itri, F., Buquicchio, C., Verga, L., Piukovics, K., Navratil, M., Collins, G. P., Jimenez, M., Fracchiolla, N. S., Labrador, J., Prezioso, L., Rossi, E., Colovic, N., Meers, S., Kulasekararaj, A., Cuccaro, A., Blennow, O., Valkovic, T., Sili, U., Ledoux, M. -P., Batinic, J., Passamonti, F., Machado, M., Duarte, R. F., Poulsen, C. B., Mendez, G. -A., Espigado, I., Demirkan, F., Cernan, M., Cattaneo, C., Petzer, V., Magliano, G., Garcia-Vidal, C., El-Ashwah, S., Gomes-Da-Silva, M., Vena, A., Ormazabal-Velez, I., van Praet, J., Dargenio, M., De-Ramon, C., Del Principe, M. I., Marques-De-Almeida, J., Wolf, D., Szotkowski, T., Obr, A., Colak, G. M., Nordlander, A., Izuzquiza, M., Cabirta, A., Zambrotta, G. P. M., Cordoba, R., Zak, P., Ammatuna, E., Mayer, J., Ilhan, O., Garcia-Sanz, R., Quattrone, Martina, Arellano, E., Nunes-Rodrigues, R., Emarah, Z., Aiello, T. F., Hanakova, M., Racil, Z., Bavastro, M., Limongelli, A., Rahimli, L., Marchesi, F., Cornely, O. A., Pagano, Livio, Quattrone M., Pagano L. (ORCID:0000-0001-8287-928X), Musto, P., Salmanton-Garcia, J., Sgherza, N., Bergantim, R., Farina, F., Glenthoj, A., Cengiz Seval, G., Weinbergerova, B., Bonuomo, V., Bilgin, Y. M., van Doesum, J., Jaksic, O., Visek, B., Falces-Romero, I., Marchetti, M., Davila-Valls, J., Martin-Perez, S., Nucci, M., Lopez-Garcia, A., Itri, F., Buquicchio, C., Verga, L., Piukovics, K., Navratil, M., Collins, G. P., Jimenez, M., Fracchiolla, N. S., Labrador, J., Prezioso, L., Rossi, E., Colovic, N., Meers, S., Kulasekararaj, A., Cuccaro, A., Blennow, O., Valkovic, T., Sili, U., Ledoux, M. -P., Batinic, J., Passamonti, F., Machado, M., Duarte, R. F., Poulsen, C. B., Mendez, G. -A., Espigado, I., Demirkan, F., Cernan, M., Cattaneo, C., Petzer, V., Magliano, G., Garcia-Vidal, C., El-Ashwah, S., Gomes-Da-Silva, M., Vena, A., Ormazabal-Velez, I., van Praet, J., Dargenio, M., De-Ramon, C., Del Principe, M. I., Marques-De-Almeida, J., Wolf, D., Szotkowski, T., Obr, A., Colak, G. M., Nordlander, A., Izuzquiza, M., Cabirta, A., Zambrotta, G. P. M., Cordoba, R., Zak, P., Ammatuna, E., Mayer, J., Ilhan, O., Garcia-Sanz, R., Quattrone, Martina, Arellano, E., Nunes-Rodrigues, R., Emarah, Z., Aiello, T. F., Hanakova, M., Racil, Z., Bavastro, M., Limongelli, A., Rahimli, L., Marchesi, F., Cornely, O. A., Pagano, Livio, Quattrone M., and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
Published: 2024

5. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Author: El-Ashwah, S., Salmanton-Garcia, J., Bilgin, Y. M., Itri, F., Zak, P., Weinbergerova, B., Verga, L., Omrani, A. S., Silva, M. G. D., Szotkowski, T., Marchetti, M., Buquicchio, C., Nucci, M., Schonlein, M., Farina, F., Besson, C., Prezioso, L., Nizamuddin, S., Davila-Valls, J., Martin-Perez, S., Bonuomo, V., Van Doesum, J., Tisi, M. C., Passamonti, F., Mendez, G. -A., Meers, S., Maertens, J., Lopez-Garcia, A., Glenthoj, A., Bonnani, M., Rinaldi, I., Ormazabal-Velez, I., Labrador, J., Kulasekararaj, A., Espigado, I., Demirkan, F., De Jonge, N., Collins, G. P., Calbacho, M., Blennow, O., Al-Khabori, M., Adzic-Vukicevic, T., Arellano, E., Miskovic, B., Mladenovic, M., Nordlander, A., Racil, Z., Ammatuna, E., Cordoba, R., Hersby, D. S., Grafe, S., Emarah, Z., Hanakova, M., Sacchi, M. V., Ijaz, M., Rahimli, L., Nunes Rodrigues, R., Zambrotta, G. P. M., Marchesi, F., Cornely, O. A., Pagano, Livio, Pagano L. (ORCID:0000-0001-8287-928X), El-Ashwah, S., Salmanton-Garcia, J., Bilgin, Y. M., Itri, F., Zak, P., Weinbergerova, B., Verga, L., Omrani, A. S., Silva, M. G. D., Szotkowski, T., Marchetti, M., Buquicchio, C., Nucci, M., Schonlein, M., Farina, F., Besson, C., Prezioso, L., Nizamuddin, S., Davila-Valls, J., Martin-Perez, S., Bonuomo, V., Van Doesum, J., Tisi, M. C., Passamonti, F., Mendez, G. -A., Meers, S., Maertens, J., Lopez-Garcia, A., Glenthoj, A., Bonnani, M., Rinaldi, I., Ormazabal-Velez, I., Labrador, J., Kulasekararaj, A., Espigado, I., Demirkan, F., De Jonge, N., Collins, G. P., Calbacho, M., Blennow, O., Al-Khabori, M., Adzic-Vukicevic, T., Arellano, E., Miskovic, B., Mladenovic, M., Nordlander, A., Racil, Z., Ammatuna, E., Cordoba, R., Hersby, D. S., Grafe, S., Emarah, Z., Hanakova, M., Sacchi, M. V., Ijaz, M., Rahimli, L., Nunes Rodrigues, R., Zambrotta, G. P. M., Marchesi, F., Cornely, O. A., Pagano, Livio, and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
Published: 2024

6. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.

Author: Busca, A., Salmanton-García, J., Marchesi, F., Farina, F., Seval, G.C., Doesum, J. Van, Jonge, N. de, Bahr, N.C., Maertens, J., Meletiadis, J., Fracchiolla, N.S., Weinbergerová, B., Verga, L., Ráčil, Z., Jiménez, M., Glenthøj, A., Blennow, O., Tanase, A.D., Schönlein, M., Prezioso, L., Khanna, N., Duarte, R.F., Žák, P., Nucci, M., Machado, M., Kulasekararaj, A., Espigado, I., Kort, E.A. de, Ribera-Santa Susana, J.M., Marchetti, M., Magliano, G., Falces-Romero, I., Ilhan, O., Ammatuna, E., Zompi, S., Tsirigotis, P., Antoniadou, A., Zambrotta, G.P.M., Nordlander, A., Karlsson, L.K., Hanakova, M., Dragonetti, G., Cabirta, A., Berg Venemyr, C., Gräfe, S., Praet, J. Van, Tragiannidis, A., Petzer, V., López-García, A., Itri, F., Groh, A., Gavriilaki, E., Dargenio, M., Rahimli, L., Cornely, O.A., Pagano, L., Busca, A., Salmanton-García, J., Marchesi, F., Farina, F., Seval, G.C., Doesum, J. Van, Jonge, N. de, Bahr, N.C., Maertens, J., Meletiadis, J., Fracchiolla, N.S., Weinbergerová, B., Verga, L., Ráčil, Z., Jiménez, M., Glenthøj, A., Blennow, O., Tanase, A.D., Schönlein, M., Prezioso, L., Khanna, N., Duarte, R.F., Žák, P., Nucci, M., Machado, M., Kulasekararaj, A., Espigado, I., Kort, E.A. de, Ribera-Santa Susana, J.M., Marchetti, M., Magliano, G., Falces-Romero, I., Ilhan, O., Ammatuna, E., Zompi, S., Tsirigotis, P., Antoniadou, A., Zambrotta, G.P.M., Nordlander, A., Karlsson, L.K., Hanakova, M., Dragonetti, G., Cabirta, A., Berg Venemyr, C., Gräfe, S., Praet, J. Van, Tragiannidis, A., Petzer, V., López-García, A., Itri, F., Groh, A., Gavriilaki, E., Dargenio, M., Rahimli, L., Cornely, O.A., and Pagano, L.
Abstract: Item does not contain fulltext, BACKGROUND: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. METHODS: This multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. RESULTS: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). CONCLUSIONS: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Published: 2023

7. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Author: Busca, A., Salmanton-Garcia, J., Marchesi, F., Farina, F., Seval, G. C., Van Doesum, J., De Jonge, N., Bahr, N. C., Maertens, J., Meletiadis, J., Fracchiolla, N. S., Weinbergerova, B., Verga, L., Racil, Z., Jimenez, M., Glenthoj, A., Blennow, O., Tanase, A. D., Schonlein, M., Prezioso, L., Khanna, N., Duarte, R. F., Zak, P., Nucci, M., Machado, M., Kulasekararaj, A., Espigado, I., De Kort, E., Ribera-Santa Susana, J. -M., Marchetti, M., Magliano, G., Falces-Romero, I., Ilhan, O., Ammatuna, E., Zompi, S., Tsirigotis, P., Antoniadou, A., Zambrotta, G. P. M., Nordlander, A., Karlsson, L. K., Hanakova, M., Dragonetti, Giulia, Cabirta, A., Berg Venemyr, C., Grafe, S., Van Praet, J., Tragiannidis, A., Petzer, V., Lopez-Garcia, A., Itri, F., Groh, A., Gavriilaki, E., Dargenio, M., Rahimli, L., Cornely, O. A., Pagano, Livio, Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Busca, A., Salmanton-Garcia, J., Marchesi, F., Farina, F., Seval, G. C., Van Doesum, J., De Jonge, N., Bahr, N. C., Maertens, J., Meletiadis, J., Fracchiolla, N. S., Weinbergerova, B., Verga, L., Racil, Z., Jimenez, M., Glenthoj, A., Blennow, O., Tanase, A. D., Schonlein, M., Prezioso, L., Khanna, N., Duarte, R. F., Zak, P., Nucci, M., Machado, M., Kulasekararaj, A., Espigado, I., De Kort, E., Ribera-Santa Susana, J. -M., Marchetti, M., Magliano, G., Falces-Romero, I., Ilhan, O., Ammatuna, E., Zompi, S., Tsirigotis, P., Antoniadou, A., Zambrotta, G. P. M., Nordlander, A., Karlsson, L. K., Hanakova, M., Dragonetti, Giulia, Cabirta, A., Berg Venemyr, C., Grafe, S., Van Praet, J., Tragiannidis, A., Petzer, V., Lopez-Garcia, A., Itri, F., Groh, A., Gavriilaki, E., Dargenio, M., Rahimli, L., Cornely, O. A., Pagano, Livio, Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Published: 2023

8. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Author: Salmanton-Garcia, J., Marchesi, F., Gomes da Silva, M., Farina, F., Davila-Valls, J., Bilgin, Y. M., Glenthoj, A., Falces-Romero, I., Van Doesum, J., Labrador, J., Buquicchio, C., El-Ashwah, S., Petzer, V., Van Praet, J., Schonlein, M., Dargenio, M., Mendez, G. -A., Meers, S., Itri, F., Giordano, A., Pinczes, L. I., Espigado, I., Stojanoski, Z., Lopez-Garcia, A., Prezioso, L., Jaksic, O., Vena, A., Fracchiolla, N. S., Gonzalez-Lopez, T. J., Colovic, N., Delia, M., Weinbergerova, B., Marchetti, M., Marques de Almeida, J., Finizio, O., Besson, C., Biernat, M. M., Valkovic, T., Lahmer, T., Cuccaro, A., Ormazabal-Velez, I., Batinic, J., Fernandez, N., De Jonge, N., Tascini, C., Anastasopoulou, A. N., Dulery, R., Del Principe, M. I., Plantefeve, G., Papa, M. V., Nucci, M., Jimenez, M., Aujayeb, A., Hernandez-Rivas, J. -A., Merelli, M., Cattaneo, C., Blennow, O., Nordlander, A., Cabirta, A., Varricchio, G., Sacchi, M. V., Cordoba, R., Arellano, E., Grafe, S. K., Wolf, D., Emarah, Z., Ammatuna, E., Hersby, D. S., Martin-Perez, S., Nunes Rodrigues, R., Rahimli, L., Pagano, Livio, Cornely, O. A., Piukovics, K., De Ramon, C., Danion, F., Yahya, A., Guidetti, A., Garcia-Vidal, C., Sili, U., Meletiadis, J., De Kort, E., Verga, L., Serrano, L., Erben, N., Di Blasi, R., Tragiannidis, A., Ribera-Santa Susana, J. -M., Ommen, H. -B., Busca, A., Coppola, N., Bergantim, R., Dragonetti, Giulia, Criscuolo, Marianna, Fianchi, Luana, Bonanni, Matteo, Soto-Silva, A., Mikulska, M., Machado, M., Shan Kho, C., Hassan, N., Gavriilaki, E., Cordini, G., Chi, L. Y. A., Eggerer, M., Hoenigl, M., Prattes, J., Jimenez-Lorenzo, M. -J., Zompi, S., Zambrotta, G. P. M., Colak, G. M., Garcia-Pouton, N., Aiello, T. F., Prin, R., Stamouli, M., Samarkos, M., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Criscuolo M., Fianchi L., Bonanni M., Salmanton-Garcia, J., Marchesi, F., Gomes da Silva, M., Farina, F., Davila-Valls, J., Bilgin, Y. M., Glenthoj, A., Falces-Romero, I., Van Doesum, J., Labrador, J., Buquicchio, C., El-Ashwah, S., Petzer, V., Van Praet, J., Schonlein, M., Dargenio, M., Mendez, G. -A., Meers, S., Itri, F., Giordano, A., Pinczes, L. I., Espigado, I., Stojanoski, Z., Lopez-Garcia, A., Prezioso, L., Jaksic, O., Vena, A., Fracchiolla, N. S., Gonzalez-Lopez, T. J., Colovic, N., Delia, M., Weinbergerova, B., Marchetti, M., Marques de Almeida, J., Finizio, O., Besson, C., Biernat, M. M., Valkovic, T., Lahmer, T., Cuccaro, A., Ormazabal-Velez, I., Batinic, J., Fernandez, N., De Jonge, N., Tascini, C., Anastasopoulou, A. N., Dulery, R., Del Principe, M. I., Plantefeve, G., Papa, M. V., Nucci, M., Jimenez, M., Aujayeb, A., Hernandez-Rivas, J. -A., Merelli, M., Cattaneo, C., Blennow, O., Nordlander, A., Cabirta, A., Varricchio, G., Sacchi, M. V., Cordoba, R., Arellano, E., Grafe, S. K., Wolf, D., Emarah, Z., Ammatuna, E., Hersby, D. S., Martin-Perez, S., Nunes Rodrigues, R., Rahimli, L., Pagano, Livio, Cornely, O. A., Piukovics, K., De Ramon, C., Danion, F., Yahya, A., Guidetti, A., Garcia-Vidal, C., Sili, U., Meletiadis, J., De Kort, E., Verga, L., Serrano, L., Erben, N., Di Blasi, R., Tragiannidis, A., Ribera-Santa Susana, J. -M., Ommen, H. -B., Busca, A., Coppola, N., Bergantim, R., Dragonetti, Giulia, Criscuolo, Marianna, Fianchi, Luana, Bonanni, Matteo, Soto-Silva, A., Mikulska, M., Machado, M., Shan Kho, C., Hassan, N., Gavriilaki, E., Cordini, G., Chi, L. Y. A., Eggerer, M., Hoenigl, M., Prattes, J., Jimenez-Lorenzo, M. -J., Zompi, S., Zambrotta, G. P. M., Colak, G. M., Garcia-Pouton, N., Aiello, T. F., Prin, R., Stamouli, M., Samarkos, M., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Criscuolo M., Fianchi L., and Bonanni M.
Abstract: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mort
Published: 2023

9. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

Author: Rossi, G., Salmanton-Garcia, J., Cattaneo, C., Marchesi, F., Davila-Valls, J., Martin-Perez, S., Itri, F., Lopez-Garcia, A., Glenthoj, A., Da Silva, M. G., Besson, C., Marchetti, M., Weinbergerova, B., Jaksic, O., Jimenez, M., Bilgin, Y. M., Van Doesum, J., Farina, F., Ak, P., Verga, L., Collins, G. P., Bonuomo, V., Praet, J. V., Nucci, M., Meers, S., Espigado, I., Fracchiolla, N. S., Valkovic, T., Poulsen, C. B., Colovic, N., Dragonetti, Giulia, Ledoux, M. -P., Tascini, C., Buquicchio, C., Blennow, O., Passamonti, F., Machado, M., Labrador, J., Duarte, R. F., Schonlein, M., Prezioso, L., Falces-Romero, I., Kulasekararaj, A., Garcia-Vidal, C., Fernandez, N., Abu-Zeinah, G., Ormazabal-Velez, I., Ad ic-Vukicevic, T., Piukovics, K., Stoma, I., Cuccaro, A., Magliano, G., Szotkowski, T., Gonzalez-Lopez, T. -J., El-Ashwah, S., Bergantim, R., Sili, U., Maertens, J., Demirkan, F., De Ramon, C., Petzer, V., Del Principe, M. I., Navratil, M., Dargenio, M., Seval, G. C., Samarkos, M., Racil, Z., Pinczes, L. I., Lahmer, T., Busca, A., Mendez, G. -A., Vena, A., Biernat, M. M., Merelli, M., Calbacho, M., Barac, A., Bavastro, M., Limongelli, A., Ilhan, O., Wolf, D., Colak, G. M., Garcia-Sanz, R., Emarah, Z., Mi kovic, B., Grafe, S. K., Mladenovic, M., Aiello, T. F., Nunez-Martin-Buitrago, L., Nordlander, A., Arellano, E., Zambrotta, G. P. M., Ammatuna, E., Cabirta, A., Sacchi, M. V., Rodrigues, R. N., Hersby, D. S., Hanakova, M., Rahimli, L., Cordoba, R., Cornely, O. A., Pagano, Livio, Marques De, Almeida, Hernandez-Rivas, Marques De Almeida, J., Hernandez-Rivas, J. A., Guidetti, A., Finizio, O., Stojanoski, Z., Cvetanoski, M., Meletiadis, J., De Jonge, N., Antic, D., Ali, N., Tisi, M. C., Serrano, L., Plantefeve, G., Khanna, N., Hoenigl, M., Cernan, M., Miranda-Castillo, C., Fernandez-Galan, M., Serris, A., Erben, N., Dulery, R., Aujayeb, A., Papa, M. V., Novak, J., Delia, M., Sapienza, G., Reizine, F., Omrani, A. S., Di Blasi, R., Lamure, S., Drgona, L., Coppola, N., Batinic, J., Al-Khabori, M., Ribera-Santa Susana, J. -M., Piedimonte, M., Loureiro-Amigo, J., Fouquet, G., Fazzi, R., Danion, F., Schubert, J., Hoell-Neugebauer, B., Bahr, N. C., Yahia, A. O., Torres-Atienza, A., Rinaldi, I., Popova, M., Ommen, H. -B., Mitra, M. E., Mikulska, M., Lacej, I., Khostelidi, S., Win, S., Vinh, D., Saleh, M., Prattes, J., Jindra, P., Guolo, F., Della Pepa, R., Chelysheva, E., Zdziarski, P., Wai-Man, V., Soto-Silva, A., Orth, H. M., Malak, S., Lorenzo De La Pena, L., Kolditz, M., Kho, C. S., Heath, C. H., Groh, A., Gavriilaki, E., Fung, M., Egger, M., De Kort, E., De Cabo, E., Cushion, T., Chowdhury, F. R., Ceesay, M. M., Brehon, M., Varricchio, G., Tafuri, A., Jimenez-Lorenzo, M. -J., Klimko, N., Tsirigotis, P., Antoniadou, A., Vehreschild, M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Rossi, G., Salmanton-Garcia, J., Cattaneo, C., Marchesi, F., Davila-Valls, J., Martin-Perez, S., Itri, F., Lopez-Garcia, A., Glenthoj, A., Da Silva, M. G., Besson, C., Marchetti, M., Weinbergerova, B., Jaksic, O., Jimenez, M., Bilgin, Y. M., Van Doesum, J., Farina, F., Ak, P., Verga, L., Collins, G. P., Bonuomo, V., Praet, J. V., Nucci, M., Meers, S., Espigado, I., Fracchiolla, N. S., Valkovic, T., Poulsen, C. B., Colovic, N., Dragonetti, Giulia, Ledoux, M. -P., Tascini, C., Buquicchio, C., Blennow, O., Passamonti, F., Machado, M., Labrador, J., Duarte, R. F., Schonlein, M., Prezioso, L., Falces-Romero, I., Kulasekararaj, A., Garcia-Vidal, C., Fernandez, N., Abu-Zeinah, G., Ormazabal-Velez, I., Ad ic-Vukicevic, T., Piukovics, K., Stoma, I., Cuccaro, A., Magliano, G., Szotkowski, T., Gonzalez-Lopez, T. -J., El-Ashwah, S., Bergantim, R., Sili, U., Maertens, J., Demirkan, F., De Ramon, C., Petzer, V., Del Principe, M. I., Navratil, M., Dargenio, M., Seval, G. C., Samarkos, M., Racil, Z., Pinczes, L. I., Lahmer, T., Busca, A., Mendez, G. -A., Vena, A., Biernat, M. M., Merelli, M., Calbacho, M., Barac, A., Bavastro, M., Limongelli, A., Ilhan, O., Wolf, D., Colak, G. M., Garcia-Sanz, R., Emarah, Z., Mi kovic, B., Grafe, S. K., Mladenovic, M., Aiello, T. F., Nunez-Martin-Buitrago, L., Nordlander, A., Arellano, E., Zambrotta, G. P. M., Ammatuna, E., Cabirta, A., Sacchi, M. V., Rodrigues, R. N., Hersby, D. S., Hanakova, M., Rahimli, L., Cordoba, R., Cornely, O. A., Pagano, Livio, Marques De, Almeida, Hernandez-Rivas, Marques De Almeida, J., Hernandez-Rivas, J. A., Guidetti, A., Finizio, O., Stojanoski, Z., Cvetanoski, M., Meletiadis, J., De Jonge, N., Antic, D., Ali, N., Tisi, M. C., Serrano, L., Plantefeve, G., Khanna, N., Hoenigl, M., Cernan, M., Miranda-Castillo, C., Fernandez-Galan, M., Serris, A., Erben, N., Dulery, R., Aujayeb, A., Papa, M. V., Novak, J., Delia, M., Sapienza, G., Reizine, F., Omrani, A. S., Di Blasi, R., Lamure, S., Drgona, L., Coppola, N., Batinic, J., Al-Khabori, M., Ribera-Santa Susana, J. -M., Piedimonte, M., Loureiro-Amigo, J., Fouquet, G., Fazzi, R., Danion, F., Schubert, J., Hoell-Neugebauer, B., Bahr, N. C., Yahia, A. O., Torres-Atienza, A., Rinaldi, I., Popova, M., Ommen, H. -B., Mitra, M. E., Mikulska, M., Lacej, I., Khostelidi, S., Win, S., Vinh, D., Saleh, M., Prattes, J., Jindra, P., Guolo, F., Della Pepa, R., Chelysheva, E., Zdziarski, P., Wai-Man, V., Soto-Silva, A., Orth, H. M., Malak, S., Lorenzo De La Pena, L., Kolditz, M., Kho, C. S., Heath, C. H., Groh, A., Gavriilaki, E., Fung, M., Egger, M., De Kort, E., De Cabo, E., Cushion, T., Chowdhury, F. R., Ceesay, M. M., Brehon, M., Varricchio, G., Tafuri, A., Jimenez-Lorenzo, M. -J., Klimko, N., Tsirigotis, P., Antoniadou, A., Vehreschild, M., Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: Objectives: Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail. Methods: We analyzed elderly patients (age groups: 65-70, 71-75, 76-80, and >80 years old) with hematologic malignancies included in the EPICOVIDEHA registry between January 2020 and July 2022. Univariable and multivariable Cox regression models were conducted to identify factors influencing death in COVID-19 patients with hematological malignancy. Results: The study included data from 3,603 elderly patients (aged 65 or older) with hematological malignancy, with a majority being male (58.1%) and a significant proportion having comorbidities. The patients were divided into four age groups, and the analysis assessed COVID-19 outcomes, vaccination status, and other variables in relation to age and pandemic waves. The 90-day survival rate for patients with COVID-19 was 71.2%, with significant differences between groups. The pandemic waves had varying impacts, with the first wave affecting patients over 80 years old, the second being more severe in 65-70, and the third being the least severe in all age groups. Factors contributing to 90-day mortality included age, comorbidities, lymphopenia, active malignancy, acute leukemia, less than three vaccine doses, severe COVID-19, and using only corticosteroids as treatment. Conclusion: These data underscore the heterogeneity of elderly hematological patients, highlight the different impacts of COVID-19 waves and the pivotal importance of vaccination, and may help in planning future healthcare efforts.
Published: 2023

10. A reply to commentaries

Author: Alessandri, G, Aschieri, F, Bobbio, A, Daini, R, Laghi, F, Nucci, M, Parolin, L, Traficante, D, Lis, A, Alessandri G., Aschieri F., Bobbio A., Daini R., Laghi F., Nucci M., Parolin L., Traficante D., Lis A., Alessandri, G, Aschieri, F, Bobbio, A, Daini, R, Laghi, F, Nucci, M, Parolin, L, Traficante, D, Lis, A, Alessandri G., Aschieri F., Bobbio A., Daini R., Laghi F., Nucci M., Parolin L., Traficante D., and Lis A.
Published: 2021

11. Teaching testing and psychological assessment. A first survey among Italian university faculty [L’INSEGNAMENTO DEGLI STRUMENTI DI ASSESSMENT PSICOLOGICO: UNA PRIMA ESPLORAZIONE NELLA COMUNITÀ ACCADEMICA ITALIANA]

Author: Alessandri, G, Aschieri, F, Bobbio, A, Daini, R, Laghi, F, Nucci, M, Parolin, L, Traficante, D, Lis, A, Alessandri G., Aschieri F., Bobbio A., Daini R., Laghi F., Nucci M., Parolin L., Traficante D., Lis A., Alessandri, G, Aschieri, F, Bobbio, A, Daini, R, Laghi, F, Nucci, M, Parolin, L, Traficante, D, Lis, A, Alessandri G., Aschieri F., Bobbio A., Daini R., Laghi F., Nucci M., Parolin L., Traficante D., and Lis A.
Abstract: Summary. This target paper focuses on the teaching of tests and psychological assessment, and presents the results of a short questionnaire on which tests and assessment procedures are presented to psychology students. The questionnaire was sent to AIP (Associazione Italiana di Psicologia) members giving at least one class on the topic of interest. The questionnaire was composed by two sections. The first section included general questions on the disciplinary sector of the class given by respondents, and on which psychological instruments were taught. The second section explored more in detail which typology of tests and instruments are taught in Italian universities. Results showed a low completion rate of the questionnaire, and a complex and scattered picture of the teaching of tests and assessment processes. This paper represents a starting point for the debate on this topic from other colleagues. This debate is particularly important given the incumbent transformation the laurea in psicologia as only requirement to practice as psychologist in Italy.
Published: 2021

12. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author: Slavin, MA, Chen, Y-C, Cordonnier, C, Cornely, OA, Cuenca-Estrella, M, Donnelly, JP, Groll, AH, Lortholary, O, Marty, FM, Nucci, M, Rex, JH, Rijnders, BJA, Thompson, GR, Verweij, PE, White, PL, Hargreaves, R, Harvey, E, Maertens, JA, Slavin, MA, Chen, Y-C, Cordonnier, C, Cornely, OA, Cuenca-Estrella, M, Donnelly, JP, Groll, AH, Lortholary, O, Marty, FM, Nucci, M, Rex, JH, Rijnders, BJA, Thompson, GR, Verweij, PE, White, PL, Hargreaves, R, Harvey, E, and Maertens, JA
Abstract: Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.
Published: 2022

13. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Author: Pagano, Livio, Salmanton-Garcia, J., Marchesi, F., Blennow, O., Gomes da Silva, M., Glenthoj, A., van Doesum, J., Bilgin, Y. M., Lopez-Garcia, A., Itri, F., Nunes Rodrigues, R., Weinbergerova, B., Farina, F., Dragonetti, Giulia, Berg Venemyr, C., van Praet, J., Jaksic, O., Valkovic, T., Falces-Romero, I., Martin-Perez, S., Jimenez, M., Davila-Valls, J., Schonlein, M., Ammatuna, E., Meers, S., Delia, M., Stojanoski, Z., Nordlander, A., Lahmer, T., Imre Pinczes, L., Buquicchio, C., Piukovics, K., Ormazabal-Velez, I., Fracchiolla, N., Samarkos, M., Mendez, G. -A., Hernandez-Rivas, J. -A., Espigado, I., Cernan, M., Petzer, V., Lamure, S., di Blasi, R., Marques de Almedia, J., Dargenio, M., Biernat, M. M., Sciume, M., de Ramon, C., de Jonge, N., Batinic, J., Aujayeb, A., Marchetti, M., Fouquet, G., Fernandez, N., Zambrotta, G., Sacchi, M. V., Guidetti, A., Demirkan, F., Prezioso, L., Racil, Z., Nucci, M., Mladenovic, M., Lievin, R., Hanakova, M., Grafe, S., Sili, U., Machado, M., Cattaneo, C., Adzic-Vukicevic, T., Verga, L., Labrador, J., Rahimli, L., Bonanni, Matteo, Passamonti, F., Pagliuca, A., Corradini, P., Hoenigl, M., Koehler, P., Busca, A., Cornely, O. A., Serrano, L., Ribera-Santa Susana, J. -M., Meletiadis, J., Tsirigotis, P., Coppola, N., Mikulska, M., Erben, N., Besson, C., Merelli, M., Gonzalez-Lopez, T. -J., Loureiro-Amigo, J., Garcia-Vidal, C., Kort, E. D., Cuccaro, A., Zompi, S., Reizine, F., Finizio, O., Dulery, R., Calbacho, M., Abu-Zeinah, G., Malak, S., Zdziarski, P., Varrichio, G., Tragiannidis, A., Plantefeve, G., Duarte, R., Danion, F., Tisi, M. C., Sakellari, I., Karthaus, M., Groh, A., Fung, M., Emarah, Z., Coronel-Ayala, O. -F., Ann Chai, L. Y., Brehon, M., Bonuomo, V., Wolf, D., Wittig, J., Vehreschild, M., Papa, M. V., Neuhann, J., Jimenez-Lorenzo, M. -J., Grothe, J., Gavriilaki, E., Garcia-Sanz, R., Garcia-Pouton, N., El-Ashwah, S. S., Eggerer, M., Cordoba, R., Colak, G. M., Arellano, E., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Bonanni M., Pagano, Livio, Salmanton-Garcia, J., Marchesi, F., Blennow, O., Gomes da Silva, M., Glenthoj, A., van Doesum, J., Bilgin, Y. M., Lopez-Garcia, A., Itri, F., Nunes Rodrigues, R., Weinbergerova, B., Farina, F., Dragonetti, Giulia, Berg Venemyr, C., van Praet, J., Jaksic, O., Valkovic, T., Falces-Romero, I., Martin-Perez, S., Jimenez, M., Davila-Valls, J., Schonlein, M., Ammatuna, E., Meers, S., Delia, M., Stojanoski, Z., Nordlander, A., Lahmer, T., Imre Pinczes, L., Buquicchio, C., Piukovics, K., Ormazabal-Velez, I., Fracchiolla, N., Samarkos, M., Mendez, G. -A., Hernandez-Rivas, J. -A., Espigado, I., Cernan, M., Petzer, V., Lamure, S., di Blasi, R., Marques de Almedia, J., Dargenio, M., Biernat, M. M., Sciume, M., de Ramon, C., de Jonge, N., Batinic, J., Aujayeb, A., Marchetti, M., Fouquet, G., Fernandez, N., Zambrotta, G., Sacchi, M. V., Guidetti, A., Demirkan, F., Prezioso, L., Racil, Z., Nucci, M., Mladenovic, M., Lievin, R., Hanakova, M., Grafe, S., Sili, U., Machado, M., Cattaneo, C., Adzic-Vukicevic, T., Verga, L., Labrador, J., Rahimli, L., Bonanni, Matteo, Passamonti, F., Pagliuca, A., Corradini, P., Hoenigl, M., Koehler, P., Busca, A., Cornely, O. A., Serrano, L., Ribera-Santa Susana, J. -M., Meletiadis, J., Tsirigotis, P., Coppola, N., Mikulska, M., Erben, N., Besson, C., Merelli, M., Gonzalez-Lopez, T. -J., Loureiro-Amigo, J., Garcia-Vidal, C., Kort, E. D., Cuccaro, A., Zompi, S., Reizine, F., Finizio, O., Dulery, R., Calbacho, M., Abu-Zeinah, G., Malak, S., Zdziarski, P., Varrichio, G., Tragiannidis, A., Plantefeve, G., Duarte, R., Danion, F., Tisi, M. C., Sakellari, I., Karthaus, M., Groh, A., Fung, M., Emarah, Z., Coronel-Ayala, O. -F., Ann Chai, L. Y., Brehon, M., Bonuomo, V., Wolf, D., Wittig, J., Vehreschild, M., Papa, M. V., Neuhann, J., Jimenez-Lorenzo, M. -J., Grothe, J., Gavriilaki, E., Garcia-Sanz, R., Garcia-Pouton, N., El-Ashwah, S. S., Eggerer, M., Cordoba, R., Colak, G. M., Arellano, E., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., and Bonanni M.
Abstract: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Published: 2022

14. Maximally superintegrable systems in flat three-dimensional space are linearizable

Author: Nucci, M. C., Campoamor Stursberg, Otto-Rudwig, Nucci, M. C., and Campoamor Stursberg, Otto-Rudwig
Abstract: All maximally superintegrable Hamiltonian systems in three-dimensional flat space derived in the work of Evans [Phys. Rev. A 41, 5666–5676 (1990)] are shown to possess hidden symmetries leading to their linearization, likewise the maximally superintegrable Hamiltonian systems in two-dimensional flat space as shown in the work of Gubbiotti and Nucci [J. Math. Phys. 58, 012902 (2017)]. We conjecture that even minimally superintegrable systems in three-dimensional flat space have hidden symmetries that make them linearizable., Ministerio de Ciencia, Innovación y Universidades (España), Depto. de Álgebra, Geometría y Topología, Fac. de Ciencias Matemáticas, TRUE, pub
Published: 2021

15. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Author: Hoenigl, M, Salmanton-Garcia, J, Walsh, TJ, Nucci, M, Neoh, CF, Jenks, JD, Lackner, M, Sprute, R, Al-Hatmi, AMS, Bassetti, M, Carlesse, F, Freiberger, T, Koehler, P, Lehrnbecher, T, Kumar, A, Prattes, J, Richardson, M, Revankar, S, Slavin, MA, Stemler, J, Spiess, B, Taj-Aldeen, SJ, Warris, A, Woo, PCY, Young, J-AH, Albus, K, Arenz, D, Arsic-Arsenijevic, V, Bouchara, J-P, Chinniah, TR, Chowdhary, A, de Hoog, GS, Dimopoulos, G, Duarte, RF, Hamal, P, Meis, JF, Mfinanga, S, Queiroz-Telles, F, Patterson, TF, Rahav, G, Rogers, TR, Rotstein, C, Wahyuningsih, R, Seidel, D, Cornely, OA, Hoenigl, M, Salmanton-Garcia, J, Walsh, TJ, Nucci, M, Neoh, CF, Jenks, JD, Lackner, M, Sprute, R, Al-Hatmi, AMS, Bassetti, M, Carlesse, F, Freiberger, T, Koehler, P, Lehrnbecher, T, Kumar, A, Prattes, J, Richardson, M, Revankar, S, Slavin, MA, Stemler, J, Spiess, B, Taj-Aldeen, SJ, Warris, A, Woo, PCY, Young, J-AH, Albus, K, Arenz, D, Arsic-Arsenijevic, V, Bouchara, J-P, Chinniah, TR, Chowdhary, A, de Hoog, GS, Dimopoulos, G, Duarte, RF, Hamal, P, Meis, JF, Mfinanga, S, Queiroz-Telles, F, Patterson, TF, Rahav, G, Rogers, TR, Rotstein, C, Wahyuningsih, R, Seidel, D, and Cornely, OA
Abstract: With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World-One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management.
Published: 2021

16. Teaching testing and psychological assessment. A first survey among Italian university faculty

Author: Alessandri, G., Aschieri, Filippo, Bobbio, Andrea, Daini, R., Laghi, F., Nucci, Massimo, Parolin, L., Traficante, Daniela, Lis, A., Aschieri F. (ORCID:0000-0002-1164-5926), Bobbio A., Nucci M., Traficante D. (ORCID:0000-0002-6861-1452), Alessandri, G., Aschieri, Filippo, Bobbio, Andrea, Daini, R., Laghi, F., Nucci, Massimo, Parolin, L., Traficante, Daniela, Lis, A., Aschieri F. (ORCID:0000-0002-1164-5926), Bobbio A., Nucci M., and Traficante D. (ORCID:0000-0002-6861-1452)
Abstract: Summary. This target paper focuses on the teaching of tests and psychological assessment, and presents the results of a short questionnaire on which tests and assessment procedures are presented to psychology students. The questionnaire was sent to AIP (Associazione Italiana di Psicologia) members giving at least one class on the topic of interest. The questionnaire was composed by two sections. The first section included general questions on the disciplinary sector of the class given by respondents, and on which psychological instruments were taught. The second section explored more in detail which typology of tests and instruments are taught in Italian universities. Results showed a low completion rate of the questionnaire, and a complex and scattered picture of the teaching of tests and assessment processes. This paper represents a starting point for the debate on this topic from other colleagues. This debate is particularly important given the incumbent transformation the laurea in psicologia as only requirement to practice as psychologist in Italy.
Published: 2021

17. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Author: Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Pagano L. (ORCID:0000-0001-8287-928X), and Dragonetti G.
Abstract: Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. Ho
Published: 2021

18. Phylogenomic analysis of a 55.1 kb 19-gene dataset resolves a monophyletic Fusarium that includes the Fusarium solani Species Complex

Author: Geiser, D. M., Al-Hatmi, A., Aoki, T., Arie, T., Balmas, V., Barnes, I., Bergstrom, G. C, Bhattacharyya, M. K. K., Blomquist, C. L., Bowden, R., Brankovics, B., Guarro, J., Ward, T., Wickes, B., Everts, K. L., Wiederhold, N. P., Wingfield, M. J., Wood, A. K. M., Xu, J. R., Carrillo, J. D., Yang, X. B., Scauflaire, J., Yli-Matilla, T., Gugino, B., Yun, S. H., Zakaria, L., Zhang, H., Fernández-Pavía, S. P., Zhang, N., Zhang, S., Zhang, X., Chang, H. X., Kim, H., Chen, C. Y., Chen, W., Gutiérrez, S., Chilvers, M. I., Chulze, S. N., Coleman, J. J., Cuomo, C. A., da Silva, G. F., de Beer, Z. W., de Hoog, G. S., Kistler, H. C., Del Castillo-Múnera, J., Del Ponte, E., Dieguez-Uribeondo, Javier, Hammond-Kosack, K., Di Pietro, A., Edel-Hermann, V., Elmer, W. H., Foroud, N. A., Fourie, G., Frandsen, R. J. N., Nucci, M., Freeman, S., Munaut, F., Freitag, Michael, Frenkel, O., Harris, L. J., Fuller, K. K., Gagkaeva, T., Gardiner, D. M., Glenn, A. E., Gold, S., Kuldau, G. A., Gordon, T., Gregory, N. F., Gryzenhout, M., Homa, M., Hong, C. F., Hornok, L., Huang, J. W., Burgess, L. W., Ilkit, M., Nicholson, P., Kulik, T., Jacobs, A., Jacobs, K., Jiang, C., Jiménez-Gasco, M. Mar, Kang, S., Kasson, M. T., Kazan, K., Kennell, J. C., Kurzai, O., Laraba, I., Laurence, M. H., Lee, T. Y., Eskalen, A., Lee, Y. W., Schmale, D. III., Lee, Y. H., Leslie, J. F., Liew, E. C. Y., O'Donnell, K., Lofton, L. W., Logrieco, A., López-Berges, M. S., Luque, A. G., Tortorano, A. M., Lysøe, E., Ma, L. J., Short, D. P., Marra, R. E., Martin, Frank N., May, S. R., McCormick, S., Pasquali, M., McGee, C. T., Meis, J. F., Urban, M., Migheli, Q., Mohamed Nor, N. M. I., Monod, M., Šišic, A., Moretti, A., Mostert, D., Mulé, G., Pfenning, L. H., Prigitano, A., Proctor, R., Busman, M., Ranque, S., Brown, D. W., Rehner, S., Rep, M., Smith, J., Rodríguez-Alvarado, G., Rose, L. J., Roth, M. G., Ruiz-Roldán, C., Saleh, A. A., Vaillancourt, L. J., Salleh, B., Sang, H., Scandiani, M., Smyth, C. W., Son, H., Spahr, E., Stajich, Jason E., Epstein, L., Steenkamp, Emma, Bushley, K., Vallad, G. E., Steinberg, C., Subramaniam, R., Suga, H., Summerell, B. A., Susca, A., Swett, C. L., Toomajian, C., Torres-Cruz, T. J., van der Lee, T., Vanderpool, D., van Diepeningen, A. D., Vaughan, M., Munkvold, G. P., Venter, E., Esposto, M. C., Vermeulen, M., Verweij, P. E., Viljoen, A., Cano-Lira, J. F., Waalwijk, C., Wallace, E. C., Walther, G., Wang, J., Geiser, D. M., Al-Hatmi, A., Aoki, T., Arie, T., Balmas, V., Barnes, I., Bergstrom, G. C, Bhattacharyya, M. K. K., Blomquist, C. L., Bowden, R., Brankovics, B., Guarro, J., Ward, T., Wickes, B., Everts, K. L., Wiederhold, N. P., Wingfield, M. J., Wood, A. K. M., Xu, J. R., Carrillo, J. D., Yang, X. B., Scauflaire, J., Yli-Matilla, T., Gugino, B., Yun, S. H., Zakaria, L., Zhang, H., Fernández-Pavía, S. P., Zhang, N., Zhang, S., Zhang, X., Chang, H. X., Kim, H., Chen, C. Y., Chen, W., Gutiérrez, S., Chilvers, M. I., Chulze, S. N., Coleman, J. J., Cuomo, C. A., da Silva, G. F., de Beer, Z. W., de Hoog, G. S., Kistler, H. C., Del Castillo-Múnera, J., Del Ponte, E., Dieguez-Uribeondo, Javier, Hammond-Kosack, K., Di Pietro, A., Edel-Hermann, V., Elmer, W. H., Foroud, N. A., Fourie, G., Frandsen, R. J. N., Nucci, M., Freeman, S., Munaut, F., Freitag, Michael, Frenkel, O., Harris, L. J., Fuller, K. K., Gagkaeva, T., Gardiner, D. M., Glenn, A. E., Gold, S., Kuldau, G. A., Gordon, T., Gregory, N. F., Gryzenhout, M., Homa, M., Hong, C. F., Hornok, L., Huang, J. W., Burgess, L. W., Ilkit, M., Nicholson, P., Kulik, T., Jacobs, A., Jacobs, K., Jiang, C., Jiménez-Gasco, M. Mar, Kang, S., Kasson, M. T., Kazan, K., Kennell, J. C., Kurzai, O., Laraba, I., Laurence, M. H., Lee, T. Y., Eskalen, A., Lee, Y. W., Schmale, D. III., Lee, Y. H., Leslie, J. F., Liew, E. C. Y., O'Donnell, K., Lofton, L. W., Logrieco, A., López-Berges, M. S., Luque, A. G., Tortorano, A. M., Lysøe, E., Ma, L. J., Short, D. P., Marra, R. E., Martin, Frank N., May, S. R., McCormick, S., Pasquali, M., McGee, C. T., Meis, J. F., Urban, M., Migheli, Q., Mohamed Nor, N. M. I., Monod, M., Šišic, A., Moretti, A., Mostert, D., Mulé, G., Pfenning, L. H., Prigitano, A., Proctor, R., Busman, M., Ranque, S., Brown, D. W., Rehner, S., Rep, M., Smith, J., Rodríguez-Alvarado, G., Rose, L. J., Roth, M. G., Ruiz-Roldán, C., Saleh, A. A., Vaillancourt, L. J., Salleh, B., Sang, H., Scandiani, M., Smyth, C. W., Son, H., Spahr, E., Stajich, Jason E., Epstein, L., Steenkamp, Emma, Bushley, K., Vallad, G. E., Steinberg, C., Subramaniam, R., Suga, H., Summerell, B. A., Susca, A., Swett, C. L., Toomajian, C., Torres-Cruz, T. J., van der Lee, T., Vanderpool, D., van Diepeningen, A. D., Vaughan, M., Munkvold, G. P., Venter, E., Esposto, M. C., Vermeulen, M., Verweij, P. E., Viljoen, A., Cano-Lira, J. F., Waalwijk, C., Wallace, E. C., Walther, G., and Wang, J.
Abstract: Scientific communication is facilitated by a data-driven, scientifically sound taxonomy that considers the end-user¿s needs and established successful practice. In 2013, the Fusarium community voiced near unanimous support for a concept of Fusarium that represented a clade comprising all agriculturally and clinically important Fusarium species, including the F. solani species complex (FSSC). Subsequently, this concept was challenged in 2015 by one research group who proposed dividing the genus Fusarium into seven genera, including the FSSC described as members of the genus Neocosmospora, with subsequent justification in 2018 based on claims that the 2013 concept of Fusarium is polyphyletic. Here, we test this claim and provide a phylogeny based on exonic nucleotide sequences of 19 orthologous protein-coding genes that strongly support the monophyly of Fusarium including the FSSC. We reassert the practical and scientific argument in support of a genus Fusarium that includes the FSSC and several other basal lineages, consistent with the longstanding use of this name among plant pathologists, medical mycologists, quarantine officials, regulatory agencies, students, and researchers with a stake in its taxonomy. In recognition of this monophyly, 40 species described as genus Neocosmospora were recombined in genus Fusarium, and nine others were renamed Fusarium. Here the global Fusarium community voices strong support for the inclusion of the FSSC in Fusarium, as it remains the best scientific, nomenclatural, and practical taxonomic option available
Published: 2021

19. Teaching testing and psychological assessment. A first survey among Italian university faculty

Author: Alessandri, G., Aschieri, Filippo, Bobbio, Andrea, Daini, R., Laghi, F., Nucci, M., Parolin, L., Traficante, Daniela, Lis, A., Aschieri F. (ORCID:0000-0002-1164-5926), Bobbio A., Traficante D. (ORCID:0000-0002-6861-1452), Alessandri, G., Aschieri, Filippo, Bobbio, Andrea, Daini, R., Laghi, F., Nucci, M., Parolin, L., Traficante, Daniela, Lis, A., Aschieri F. (ORCID:0000-0002-1164-5926), Bobbio A., and Traficante D. (ORCID:0000-0002-6861-1452)
Abstract: Summary. This target paper focuses on the teaching of tests and psychological assessment, and presents the results of a short questionnaire on which tests and assessment procedures are presented to psychology students. The questionnaire was sent to AIP (Associazione Italiana di Psicologia) members giving at least one class on the topic of interest. The questionnaire was composed by two sections. The first section included general questions on the disciplinary sector of the class given by respondents, and on which psychological instruments were taught. The second section explored more in detail which typology of tests and instruments are taught in Italian universities. Results showed a low completion rate of the questionnaire, and a complex and scattered picture of the teaching of tests and assessment processes. This paper represents a starting point for the debate on this topic from other colleagues. This debate is particularly important given the incumbent transformation the laurea in psicologia as only requirement to practice as psychologist in Italy.
Published: 2021

20. A reply to commentaries

Author: Alessandri, G., Aschieri, Filippo, Bobbio, Andrea, Daini, R., Laghi, F., Nucci, M., Parolin, L., Traficante, Daniela, Lis, A., Aschieri F. (ORCID:0000-0002-1164-5926), Bobbio A., Traficante D. (ORCID:0000-0002-6861-1452), Alessandri, G., Aschieri, Filippo, Bobbio, Andrea, Daini, R., Laghi, F., Nucci, M., Parolin, L., Traficante, Daniela, Lis, A., Aschieri F. (ORCID:0000-0002-1164-5926), Bobbio A., and Traficante D. (ORCID:0000-0002-6861-1452)
Abstract: A reply to commentaries
Published: 2021

21. Do high MICs predict the outcome in invasive fusariosis?

Author: Nucci, M., Jenks, J., Thompson, G. R., Hoenigl, M., Dos Santos, M. C., Forghieri, F., Rico, J. C., Bonuomo, V., Lopez-Soria, L., Lass-Florl, C., Candoni, A., Garcia-Vidal, C., Cattaneo, C., Buil, J., Rabagliati, R., Roiz, M. P., Gudiol, C., Fracchiolla, N., Campos-Herrero, M. I., Delia, M., Farina, F., Fortun, J., Nadali, G., Sastre, E., Colombo, A. L., Perez Nadales, E., Alastruey-Izquierdo, A., Pagano, Livio, Pagano L. (ORCID:0000-0001-8287-928X), Nucci, M., Jenks, J., Thompson, G. R., Hoenigl, M., Dos Santos, M. C., Forghieri, F., Rico, J. C., Bonuomo, V., Lopez-Soria, L., Lass-Florl, C., Candoni, A., Garcia-Vidal, C., Cattaneo, C., Buil, J., Rabagliati, R., Roiz, M. P., Gudiol, C., Fracchiolla, N., Campos-Herrero, M. I., Delia, M., Farina, F., Fortun, J., Nadali, G., Sastre, E., Colombo, A. L., Perez Nadales, E., Alastruey-Izquierdo, A., Pagano, Livio, and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: BACKGROUND: Invasive fusariosis (IF) affects mostly severely immunocompromised hosts and is associated with poor outcome. Since Fusarium species exhibit high MICs for most antifungal agents, this could explain the poor prognosis. However, a clear-cut correlation between MIC and outcome has not been established. OBJECTIVE: To evaluate the correlation between MIC and outcome (6 week death rate) in patients with IF. METHODS: We performed a multicentre retrospective study of patients with IF who received treatment and had MIC levels determined by EUCAST or CLSI for the drug(s) used during treatment. We compared the MIC50 and MIC distribution among survivors and patients who died within 6 weeks from the diagnosis of IF. RESULTS: Among 88 patients with IF, 74 had haematological diseases. Primary treatment was monotherapy in 52 patients (voriconazole in 27) and combination therapy in 36 patients (liposomal amphotericin B + voriconazole in 23). The MIC50 and range for the five most frequent agents tested were: voriconazole 8 mg/L (range 0.5-64), amphotericin B 2 mg/L (range 0.25-64), posaconazole 16 mg/L (range 0.5-64), itraconazole 32 mg/L (range 4-64), and isavuconazole 32 mg/L (range 8-64). There was no difference in MIC50 and MIC distribution among survivors and patients who died. By contrast, persistent neutropenia and receipt of corticosteroids were strong predictors of 6 week mortality. CONCLUSIONS: Our study did not show any correlation between MIC and mortality at 6 weeks in patients with IF.
Published: 2021

22. Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients

Author: Stemler, J., Bruns, C., Mellinghoff, S.C., Alakel, N., Akan, H., Ananda-Rajah, M., Auberger, J., Bojko, P., Chandrasekar, P.H., Chayakulkeeree, M., Cozzi, J.A., Kort, E.A. de, Groll, A.H., Heath, C.H., Henze, L., Hernandez Jimenez, M., Kanj, S.S., Khanna, N., Koldehoff, M., Lee, D.G., Mager, A., Marchesi, F., Martino-Bufarull, R., Nucci, M., Oksi, J., Pagano, L., Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-Hieber, M., Sidharthan, N., Soler-Palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O.A., Koehler, P., Stemler, J., Bruns, C., Mellinghoff, S.C., Alakel, N., Akan, H., Ananda-Rajah, M., Auberger, J., Bojko, P., Chandrasekar, P.H., Chayakulkeeree, M., Cozzi, J.A., Kort, E.A. de, Groll, A.H., Heath, C.H., Henze, L., Hernandez Jimenez, M., Kanj, S.S., Khanna, N., Koldehoff, M., Lee, D.G., Mager, A., Marchesi, F., Martino-Bufarull, R., Nucci, M., Oksi, J., Pagano, L., Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-Hieber, M., Sidharthan, N., Soler-Palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O.A., and Koehler, P.
Abstract: Contains fulltext : 218254.pdf (publisher's version ) (Open Access), Baseline chest computed tomography (BCT) in high-risk hematology patients allows for the early diagnosis of invasive pulmonary aspergillosis (IPA). The distribution of BCT implementation in hematology departments and impact on outcome is unknown. A web-based questionnaire was designed. International scientific bodies were invited. The estimated numbers of annually treated hematology patients, chest imaging timepoints and techniques, IPA rates, and follow-up imaging were assessed. In total, 142 physicians from 43 countries participated. The specialties included infectious diseases (n = 69; 49%), hematology (n = 68; 48%), and others (n = 41; 29%). BCT was performed in 57% (n = 54) of 92 hospitals. Upon the diagnosis of malignancy or admission, 48% and 24% performed BCT, respectively, and X-ray was performed in 48% and 69%, respectively. BCT was more often used in hematopoietic cell transplantation and in relapsed acute leukemia. European centers performed BCT in 59% and non-European centers in 53%. Median estimated IPA rate was 8% and did not differ between BCT (9%; IQR 5-15%) and non-BCT centers (7%; IQR 5-10%) (p = 0.69). Follow-up computed tomography (CT) for IPA was performed in 98% (n = 90) of centers. In high-risk hematology patients, baseline CT is becoming a standard-of-care. Chest X-ray, while inferior, is still widely used. Randomized, controlled trials are needed to investigate the impact of BCT on patient outcome.
Published: 2020

23. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author: Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., Pappas, P.G., Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., and Pappas, P.G.
Abstract: Contains fulltext : 225781.pdf (Publisher’s version ) (Open Access), BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Published: 2020

24. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author: Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, B-J, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z, Roilides, E, Ruhnke, M, Prokop, CS, Shoham, S, Slavin, MA, Stevens, DA, Thompson, GR, Vazquez, JA, Viscoli, C, Walsh, TJ, Warris, A, Wheat, LJ, White, PL, Zaoutis, TE, Pappas, PG, Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, B-J, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z, Roilides, E, Ruhnke, M, Prokop, CS, Shoham, S, Slavin, MA, Stevens, DA, Thompson, GR, Vazquez, JA, Viscoli, C, Walsh, TJ, Warris, A, Wheat, LJ, White, PL, Zaoutis, TE, and Pappas, PG
Abstract: BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Published: 2020

25. Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients

Author: Stemler, J., Bruns, C., Mellinghoff, S.C., Alakel, N., Akan, H., Ananda-Rajah, M., Auberger, J., Bojko, P., Chandrasekar, P.H., Chayakulkeeree, M., Cozzi, J.A., Kort, E.A. de, Groll, A.H., Heath, C.H., Henze, L., Hernandez Jimenez, M., Kanj, S.S., Khanna, N., Koldehoff, M., Lee, D.G., Mager, A., Marchesi, F., Martino-Bufarull, R., Nucci, M., Oksi, J., Pagano, L., Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-Hieber, M., Sidharthan, N., Soler-Palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O.A., Koehler, P., Stemler, J., Bruns, C., Mellinghoff, S.C., Alakel, N., Akan, H., Ananda-Rajah, M., Auberger, J., Bojko, P., Chandrasekar, P.H., Chayakulkeeree, M., Cozzi, J.A., Kort, E.A. de, Groll, A.H., Heath, C.H., Henze, L., Hernandez Jimenez, M., Kanj, S.S., Khanna, N., Koldehoff, M., Lee, D.G., Mager, A., Marchesi, F., Martino-Bufarull, R., Nucci, M., Oksi, J., Pagano, L., Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-Hieber, M., Sidharthan, N., Soler-Palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O.A., and Koehler, P.
Abstract: Contains fulltext : 218254.pdf (publisher's version ) (Open Access), Baseline chest computed tomography (BCT) in high-risk hematology patients allows for the early diagnosis of invasive pulmonary aspergillosis (IPA). The distribution of BCT implementation in hematology departments and impact on outcome is unknown. A web-based questionnaire was designed. International scientific bodies were invited. The estimated numbers of annually treated hematology patients, chest imaging timepoints and techniques, IPA rates, and follow-up imaging were assessed. In total, 142 physicians from 43 countries participated. The specialties included infectious diseases (n = 69; 49%), hematology (n = 68; 48%), and others (n = 41; 29%). BCT was performed in 57% (n = 54) of 92 hospitals. Upon the diagnosis of malignancy or admission, 48% and 24% performed BCT, respectively, and X-ray was performed in 48% and 69%, respectively. BCT was more often used in hematopoietic cell transplantation and in relapsed acute leukemia. European centers performed BCT in 59% and non-European centers in 53%. Median estimated IPA rate was 8% and did not differ between BCT (9%; IQR 5-15%) and non-BCT centers (7%; IQR 5-10%) (p = 0.69). Follow-up computed tomography (CT) for IPA was performed in 98% (n = 90) of centers. In high-risk hematology patients, baseline CT is becoming a standard-of-care. Chest X-ray, while inferior, is still widely used. Randomized, controlled trials are needed to investigate the impact of BCT on patient outcome.
Published: 2020

26. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author: Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., Pappas, P.G., Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., and Pappas, P.G.
Abstract: Contains fulltext : 225781.pdf (Publisher’s version ) (Open Access), BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Published: 2020

27. Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients

Author: Stemler, J., Bruns, C., Mellinghoff, S.C., Alakel, N., Akan, H., Ananda-Rajah, M., Auberger, J., Bojko, P., Chandrasekar, P.H., Chayakulkeeree, M., Cozzi, J.A., Kort, E.A. de, Groll, A.H., Heath, C.H., Henze, L., Hernandez Jimenez, M., Kanj, S.S., Khanna, N., Koldehoff, M., Lee, D.G., Mager, A., Marchesi, F., Martino-Bufarull, R., Nucci, M., Oksi, J., Pagano, L., Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-Hieber, M., Sidharthan, N., Soler-Palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O.A., Koehler, P., Stemler, J., Bruns, C., Mellinghoff, S.C., Alakel, N., Akan, H., Ananda-Rajah, M., Auberger, J., Bojko, P., Chandrasekar, P.H., Chayakulkeeree, M., Cozzi, J.A., Kort, E.A. de, Groll, A.H., Heath, C.H., Henze, L., Hernandez Jimenez, M., Kanj, S.S., Khanna, N., Koldehoff, M., Lee, D.G., Mager, A., Marchesi, F., Martino-Bufarull, R., Nucci, M., Oksi, J., Pagano, L., Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-Hieber, M., Sidharthan, N., Soler-Palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O.A., and Koehler, P.
Abstract: Contains fulltext : 218254.pdf (publisher's version ) (Open Access), Baseline chest computed tomography (BCT) in high-risk hematology patients allows for the early diagnosis of invasive pulmonary aspergillosis (IPA). The distribution of BCT implementation in hematology departments and impact on outcome is unknown. A web-based questionnaire was designed. International scientific bodies were invited. The estimated numbers of annually treated hematology patients, chest imaging timepoints and techniques, IPA rates, and follow-up imaging were assessed. In total, 142 physicians from 43 countries participated. The specialties included infectious diseases (n = 69; 49%), hematology (n = 68; 48%), and others (n = 41; 29%). BCT was performed in 57% (n = 54) of 92 hospitals. Upon the diagnosis of malignancy or admission, 48% and 24% performed BCT, respectively, and X-ray was performed in 48% and 69%, respectively. BCT was more often used in hematopoietic cell transplantation and in relapsed acute leukemia. European centers performed BCT in 59% and non-European centers in 53%. Median estimated IPA rate was 8% and did not differ between BCT (9%; IQR 5-15%) and non-BCT centers (7%; IQR 5-10%) (p = 0.69). Follow-up computed tomography (CT) for IPA was performed in 98% (n = 90) of centers. In high-risk hematology patients, baseline CT is becoming a standard-of-care. Chest X-ray, while inferior, is still widely used. Randomized, controlled trials are needed to investigate the impact of BCT on patient outcome.
Published: 2020

28. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author: Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., Pappas, P.G., Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., and Pappas, P.G.
Abstract: Contains fulltext : 225781.pdf (Publisher’s version ) (Open Access), BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Published: 2020

29. Baseline chest computed tomography as standard of care in high‐risk hematology patients

Author: Stemler, J., Bruns, C., Mellinghoff, S. C., Alakel, N., Akan, H., Ananda-rajah, M., Auberger, J., Bojko, P., Chandrasekar, P. H., Chayakulkeeree, M., Cozzi, J. A., de Kort, E. A., Groll, A. H., Heath, C. H., Henze, L., Jimenez, M. H., Kanj, S. S., Khanna, N., Koldehoff, M., Lee, D. -G., Mager, A., Marchesi, F., Martino-bufarull, R., Nucci, M., Oksi, J., Pagano, Livio, Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-hieber, M., Sidharthan, N., Soler-palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O. A., Koehler, P., Pagano L. (ORCID:0000-0001-8287-928X), Stemler, J., Bruns, C., Mellinghoff, S. C., Alakel, N., Akan, H., Ananda-rajah, M., Auberger, J., Bojko, P., Chandrasekar, P. H., Chayakulkeeree, M., Cozzi, J. A., de Kort, E. A., Groll, A. H., Heath, C. H., Henze, L., Jimenez, M. H., Kanj, S. S., Khanna, N., Koldehoff, M., Lee, D. -G., Mager, A., Marchesi, F., Martino-bufarull, R., Nucci, M., Oksi, J., Pagano, Livio, Phillips, B., Prattes, J., Pyrpasopoulou, A., Rabitsch, W., Schalk, E., Schmidt-hieber, M., Sidharthan, N., Soler-palacin, P., Stern, A., Weinbergerova, B., El Zakhem, A., Cornely, O. A., Koehler, P., and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: Baseline chest computed tomography (BCT) in high‐risk hematology patients allows for the early diagnosis of invasive pulmonary aspergillosis (IPA). The distribution of BCT implementation in hematology departments and impact on outcome is unknown. A web‐based questionnaire was designed. International scientific bodies were invited. The estimated numbers of annually treated hematology patients, chest imaging timepoints and techniques, IPA rates, and follow‐up imaging were assessed. In total, 142 physicians from 43 countries participated. The specialties included infectious diseases (n = 69; 49%), hematology (n = 68; 48%), and others (n = 41; 29%). BCT was performed in 57% (n = 54) of 92 hospitals. Upon the diagnosis of malignancy or admission, 48% and 24% performed BCT, respectively, and X‐ray was performed in 48% and 69%, respectively. BCT was more often used in hematopoietic cell transplantation and in relapsed acute leukemia. European centers performed BCT in 59% and non‐European centers in 53%. Median estimated IPA rate was 8% and did not differ between BCT (9%; IQR 5–15%) and non‐BCT centers (7%; IQR 5–10%) (p = 0.69). Follow‐up computed tomography (CT) for IPA was performed in 98% (n = 90) of centers. In high‐risk hematology patients, baseline CT is becoming a standard‐of‐care. Chest X‐ray, while inferior, is still widely used. Randomized, controlled trials are needed to investigate the impact of BCT on patient outcome.
Published: 2020

30. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Author: Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., Mellinghoff, S. C., Mer, M., Pana, Z. D., Seidel, D., Sheppard, D. C., Wahba, R., Akova, M., Alanio, A., Al-Hatmi, A. M. S., Arikan-Akdagli, S., Badali, H., Ben-Ami, R., Bonifaz, A., Bretagne, S., Castagnola, E., Chayakulkeeree, M., Colombo, A. L., Corzo-Leon, D. E., Drgona, L., Groll, A. H., Guinea, J., Heussel, C. -P., Ibrahim, A. S., Kanj, S. S., Klimko, N., Lackner, M., Lamoth, F., Lanternier, F., Lass-Floerl, C., Lee, D. -G., Lehrnbecher, T., Lmimouni, B. E., Mares, M., Maschmeyer, G., Meis, J. F., Meletiadis, J., Morrissey, C. O., Nucci, M., Oladele, R., Pagano, L., Pasqualotto, A., Patel, A., Racil, Z., Richardson, M., Roilides, E., Ruhnke, M., Seyedmousavi, S., Sidharthan, N., Singh, N., Sinko, J., Skiada, A., Slavin, M., Soman, R., Spellberg, B., Steinbach, W., Tan, B. H., Ullmann, A. J., Vehreschild, J. J., Vehreschild, M. J. G. T., Walsh, T. J., White, P. L., Wiederhold, N. P., Zaoutis, T., Chakrabarti, A., Pagano L. (ORCID:0000-0001-8287-928X), Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., Mellinghoff, S. C., Mer, M., Pana, Z. D., Seidel, D., Sheppard, D. C., Wahba, R., Akova, M., Alanio, A., Al-Hatmi, A. M. S., Arikan-Akdagli, S., Badali, H., Ben-Ami, R., Bonifaz, A., Bretagne, S., Castagnola, E., Chayakulkeeree, M., Colombo, A. L., Corzo-Leon, D. E., Drgona, L., Groll, A. H., Guinea, J., Heussel, C. -P., Ibrahim, A. S., Kanj, S. S., Klimko, N., Lackner, M., Lamoth, F., Lanternier, F., Lass-Floerl, C., Lee, D. -G., Lehrnbecher, T., Lmimouni, B. E., Mares, M., Maschmeyer, G., Meis, J. F., Meletiadis, J., Morrissey, C. O., Nucci, M., Oladele, R., Pagano, L., Pasqualotto, A., Patel, A., Racil, Z., Richardson, M., Roilides, E., Ruhnke, M., Seyedmousavi, S., Sidharthan, N., Singh, N., Sinko, J., Skiada, A., Slavin, M., Soman, R., Spellberg, B., Steinbach, W., Tan, B. H., Ullmann, A. J., Vehreschild, J. J., Vehreschild, M. J. G. T., Walsh, T. J., White, P. L., Wiederhold, N. P., Zaoutis, T., Chakrabarti, A., and Pagano L. (ORCID:0000-0001-8287-928X)
Abstract: Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the “One World One Guideline” initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.
Published: 2019

31. Glaucoma drug therapy in pregnancy: literature review and Teratology Information Service (TIS) case series

Author: Pellegrino, Marcella, D'Oria, Luisa, De Luca, Carmen, Chiaradia, Giacomina, Licameli, Angelo, Neri, Caterina, Nucci, Marta, Visconti, Daniela, Caruso, Alessandro, De Santis, Marco, Pellegrino M, D’Oria L, De Luca C, Chiaradia G, Licameli A, Neri C, Nucci M, Visconti D, Caruso A (ORCID:0000-0002-4749-3207), De Santis M. (ORCID:0000-0002-1388-0014), Pellegrino, Marcella, D'Oria, Luisa, De Luca, Carmen, Chiaradia, Giacomina, Licameli, Angelo, Neri, Caterina, Nucci, Marta, Visconti, Daniela, Caruso, Alessandro, De Santis, Marco, Pellegrino M, D’Oria L, De Luca C, Chiaradia G, Licameli A, Neri C, Nucci M, Visconti D, Caruso A (ORCID:0000-0002-4749-3207), and De Santis M. (ORCID:0000-0002-1388-0014)
Abstract: BACKGROUND: there are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. METHOD: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as part of multidrug therapy. We selected a control group of 187 healthy pregnant women. RESULTS: topical use of timolol alone or timolol in combination with other antiglaucoma medications don't influence pregnancy or fetal/neonatal outcomes. CONCLUSION: beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
Published: 2018

32. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials

Author: Kullberg, B.J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.A., Garbino, J., Yan, J.L., Aram, J., Capparella, M.R., Conte, U., Schlamm, H., Swanson, R., Herbrecht, R., Kullberg, B.J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.A., Garbino, J., Yan, J.L., Aram, J., Capparella, M.R., Conte, U., Schlamm, H., Swanson, R., and Herbrecht, R.
Abstract: Contains fulltext : 177342.pdf (publisher's version ) (Open Access), Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non- albicans Candida species. Methods: Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofungin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; ClinicalTrials.gov). In all studies, patients with culture-confirmed invasive candidiasis received a single intravenous (iv) loading dose of anidulafungin 200 mg on day 1, followed by 100 mg once-daily. Switch to oral fluconazole or voriconazole was permitted after 5-10 days of iv treatment in all studies except one. Antifungal treatment (iv plus oral therapy if applicable) was maintained for >/=14 days after the last positive Candida culture. The primary endpoint was successful global response at end of iv therapy (EOivT) in the modified ITT (mITT) population. Results: In total, 539 patients were included (mITT population). The most common baseline Candida species were Candida albicans (47.9%), Candida glabrata (21.0%), Candida tropicalis (13.7%), Candida parapsilosis (13.2%) and Candida krusei (3.5%). Median duration of anidulafungin iv treatment was 10.0 days. The global response success rate at EOivT was 76.4% (95% CI 72.9%-80.0%). All-cause mortality was 13.0% on day 14 and 19.1% on day 28. Adverse events (AEs) were consistent with the known AE profile for anidulafungin. Conclusions: These data demonstrate that anidulafungin is effective for treatment of candidaemia and invasive candidiasis in a broad patient population.
Published: 2017

33. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials

Author: Kullberg, B.J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.A., Garbino, J., Yan, J.L., Aram, J., Capparella, M.R., Conte, U., Schlamm, H., Swanson, R., Herbrecht, R., Kullberg, B.J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.A., Garbino, J., Yan, J.L., Aram, J., Capparella, M.R., Conte, U., Schlamm, H., Swanson, R., and Herbrecht, R.
Abstract: Contains fulltext : 177342.pdf (publisher's version ) (Open Access), Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non- albicans Candida species. Methods: Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofungin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; ClinicalTrials.gov). In all studies, patients with culture-confirmed invasive candidiasis received a single intravenous (iv) loading dose of anidulafungin 200 mg on day 1, followed by 100 mg once-daily. Switch to oral fluconazole or voriconazole was permitted after 5-10 days of iv treatment in all studies except one. Antifungal treatment (iv plus oral therapy if applicable) was maintained for >/=14 days after the last positive Candida culture. The primary endpoint was successful global response at end of iv therapy (EOivT) in the modified ITT (mITT) population. Results: In total, 539 patients were included (mITT population). The most common baseline Candida species were Candida albicans (47.9%), Candida glabrata (21.0%), Candida tropicalis (13.7%), Candida parapsilosis (13.2%) and Candida krusei (3.5%). Median duration of anidulafungin iv treatment was 10.0 days. The global response success rate at EOivT was 76.4% (95% CI 72.9%-80.0%). All-cause mortality was 13.0% on day 14 and 19.1% on day 28. Adverse events (AEs) were consistent with the known AE profile for anidulafungin. Conclusions: These data demonstrate that anidulafungin is effective for treatment of candidaemia and invasive candidiasis in a broad patient population.
Published: 2017

34. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

Author: Cornely, O. A., Leguay, T., Maertens, J., Vehreschild, M. J. G. T., Anagnostopoulos, A., Castagnola, C., Verga, L., Rieger, C., Kondakci, M., Harter, G., Duarte, R. F., Allione, B., Cordonnier, C., Heussel, C. P., Morrissey, C. O., Agrawal, S. G., Peter Donnelly, J., Bresnik, M., Hawkins, M. J., Garner, W., Gokbuget, N., Jarchum, G., Dictar, M., Ramirez Borga, S., Valledor, A., Knoebl, P., Greil, R., Linkesch, W., Sill, H., De Prijck, B., Sonet, A., Theunissen, K., Selleslag, D., Vargas Schwarzbold, A., Nucci, M. L. M., Lopes de Castro Lobo, C., Fogliatto, L., Bonmati, C., Turlure, P., Herbrecht, R., Thiebaut, A., Michallet, M., Egerer, G., Silling, G., Pfreundschuh, M., Hasenkamp, J., Kraemer, D. M., Topp, M., Heinz, W., Junghanss, C., Schaich, M. A., Parmentier, S., Roellig, C., Beck, H. J., Huttmann, A., Mousset, S., Duenzinger, U. N., Schwartz, S., Haerter, G., Ostermann, H., Tsirigotis, P., Matsouka, P., Angelopoulou, M. K., Karakantza, M., Spyridonidis, A., Kolomansky, A., Moses, A., Horowitz, N., Rahav, G., Aversa, F., Velardi, A., Pagano, Livio, Gentile, Giuseppe, Gobbi, M., Luppi, M., Nosari, A. M., Rambaldi, A., Candoni, A., Marbello, L., Rossi, G., Pogliani, E., Moreira, I., Nunes, A., Botelho de Sousa, A., Rubio Tejero, A. I., Vallejo, C., Vazquez, L., Besalduch Vidal, J., Gomez-Garcia de Soria, V., Jurado Chacon, M., Gonzalez Campos, J., Olavarria, E., Barba, P., de la Serna Torroba, J., Duarte, R., Heim, D., Zimmerli, S., Gerber, B., Akova, M., Bolaman, A. Z., Tabak, F., Akan, H., Senol, E., Pagano L. (ORCID:0000-0001-8287-928X), Gentile G., Cornely, O. A., Leguay, T., Maertens, J., Vehreschild, M. J. G. T., Anagnostopoulos, A., Castagnola, C., Verga, L., Rieger, C., Kondakci, M., Harter, G., Duarte, R. F., Allione, B., Cordonnier, C., Heussel, C. P., Morrissey, C. O., Agrawal, S. G., Peter Donnelly, J., Bresnik, M., Hawkins, M. J., Garner, W., Gokbuget, N., Jarchum, G., Dictar, M., Ramirez Borga, S., Valledor, A., Knoebl, P., Greil, R., Linkesch, W., Sill, H., De Prijck, B., Sonet, A., Theunissen, K., Selleslag, D., Vargas Schwarzbold, A., Nucci, M. L. M., Lopes de Castro Lobo, C., Fogliatto, L., Bonmati, C., Turlure, P., Herbrecht, R., Thiebaut, A., Michallet, M., Egerer, G., Silling, G., Pfreundschuh, M., Hasenkamp, J., Kraemer, D. M., Topp, M., Heinz, W., Junghanss, C., Schaich, M. A., Parmentier, S., Roellig, C., Beck, H. J., Huttmann, A., Mousset, S., Duenzinger, U. N., Schwartz, S., Haerter, G., Ostermann, H., Tsirigotis, P., Matsouka, P., Angelopoulou, M. K., Karakantza, M., Spyridonidis, A., Kolomansky, A., Moses, A., Horowitz, N., Rahav, G., Aversa, F., Velardi, A., Pagano, Livio, Gentile, Giuseppe, Gobbi, M., Luppi, M., Nosari, A. M., Rambaldi, A., Candoni, A., Marbello, L., Rossi, G., Pogliani, E., Moreira, I., Nunes, A., Botelho de Sousa, A., Rubio Tejero, A. I., Vallejo, C., Vazquez, L., Besalduch Vidal, J., Gomez-Garcia de Soria, V., Jurado Chacon, M., Gonzalez Campos, J., Olavarria, E., Barba, P., de la Serna Torroba, J., Duarte, R., Heim, D., Zimmerli, S., Gerber, B., Akova, M., Bolaman, A. Z., Tabak, F., Akan, H., Senol, E., Pagano L. (ORCID:0000-0001-8287-928X), and Gentile G.
Abstract: Objectives: To prevent invasive fungal disease (IFD) in adult patients undergoing remission-induction chemotherapy for newly diagnosed acute lymphoblastic leukaemia (ALL). Patients and methods: In a double-blind multicentre Phase 3 study, patients received prophylactic liposomal amphotericin B (L-AMB) at 5 mg/kg intravenously or placebo twice weekly in a 2:1 random allocation during remission-induction treatment. The primary endpoint was the development of proven or probable IFD. Secondary endpoints included those focused on the safety and tolerability of prophylactic L-AMB. Results: Three hundred and fifty-five patients from 86 centres in Europe and South America received at least one dose of L-AMB (n = 237) or placebo (n = 118). Rates of proven and probable IFD assessed independently were 7.9%(18/228) in the L-AMB group and 11.7%(13/111) in the placebo group (P = 0.24). Rates of possible IFD were 4.8% (11/228) in the L-AMB and 5.4% (6/111) in the placebo group (P = 0.82). The remission-induction phase was a median of 22 days for both groups. Overall mortality was similar between the groups: 7.2% (17/237) for L-AMB and 6.8% (8/118) for placebo (P = 1.00). Hypokalaemia and creatinine increase were significantly more frequent with L-AMB. Conclusions: The IFD rate among adult patients undergoing remission-induction chemotherapy for newly diagnosed ALL was 11.7%in the placebo group, andwas not significantly different in patients receiving L-AMB, suggesting that the L-AMB regimen studied is not effective as prophylaxis against IFD. The IFD rate appears higher than previously reported, warranting further investigation. Tolerability of L-AMB was what might be expected. Further studies are needed to determine the optimal antifungal strategy during remission-induction chemotherapy of ALL.
Published: 2017

35. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study

Author: Bassetti, M., Peghin, M., Carnelutti, A., Righi, E., Merelli, M., Ansaldi, F., Trucchi, C., Alicino, C., Sartor, A., Toniutto, P., Wauters, J., Laleman, W., Tascini, C., Menichetti, F., Luzzati, R., Brugnaro, P., Mesini, A., Raviolo, S., De Rosa, F. G., Lagunes, L., Rello, J., Dimopoulos, G., Colombo, A. L., Nucci, M., Vena, A., Bouza, E., Munoz, P., Tumbarello, M., Losito, R., Martin-Loeches, I., Viscoli, C., Tumbarello M. (ORCID:0000-0002-9519-8552), Bassetti, M., Peghin, M., Carnelutti, A., Righi, E., Merelli, M., Ansaldi, F., Trucchi, C., Alicino, C., Sartor, A., Toniutto, P., Wauters, J., Laleman, W., Tascini, C., Menichetti, F., Luzzati, R., Brugnaro, P., Mesini, A., Raviolo, S., De Rosa, F. G., Lagunes, L., Rello, J., Dimopoulos, G., Colombo, A. L., Nucci, M., Vena, A., Bouza, E., Munoz, P., Tumbarello, M., Losito, R., Martin-Loeches, I., Viscoli, C., and Tumbarello M. (ORCID:0000-0002-9519-8552)
Abstract: Purpose: The aim of the study was to describe the characteristics of cirrhotic patients with candidemia and intra-abdominal candidiasis (IAC) and to evaluate the risk factors associated with 30-day mortality. Methods: A multicenter multinational retrospective study including all consecutive episodes of candidemia and IAC in adult patients with liver cirrhosis in 14 European hospitals during the period 2011–2013 was performed. Results: A total of 241 episodes (169 candidemia, 72 IAC) were included. Most Candida infections were acquired in hospital (208, 86.3%), mainly in the intensive care unit (ICU) (121, 50.2%). At clinical presentation, fever was seen in 60.6% of episodes (146/241) and septic shock in 34.9% (84/241). C. albicans was the most common species (found in 131 episodes, 54.4%), followed by C. glabrata (35, 14.5%) and C. parapsilosis (34, 14.1%). Overall, the 30-day mortality was 35.3%. Multivariable analysis identified candidemia (OR 2.2, 95% CI 1.2–4.5) and septic shock (OR 3.2, 95% CI 1.7–6) as independent factors associated with 30-day mortality. Adequate antifungal treatment (OR 0.4, 95% CI 0.3–0.9) was associated with survival benefit. Conclusions: A shift towards increasing prevalence of C. glabrata and C. parapsilosis species in patients with liver disease was documented. Candidemia and IAC were associated with significant mortality in cirrhotic patients. Thirty-day mortality was associated with candidemia and severe clinical presentation, whereas adequate antifungal treatment improved the prognosis.
Published: 2017

36. Trans-disciplinary approach in participative processes to a local scale management of landscape resources

Author: Marcheggiani, E, Castellani, V, Sala, S, Galli, A, Nucci, M, Nucci, M., CASTELLANI, VALENTINA, SALA, SERENELLA, Marcheggiani, E, Castellani, V, Sala, S, Galli, A, Nucci, M, Nucci, M., CASTELLANI, VALENTINA, and SALA, SERENELLA
Abstract: The aim of this work is to illustrate the current state of a wider project whose general objective is to integrate a number of scientific and methodological approaches and technologies, in order to support local authorities and stakeholders, especially those acting in marginal areas, toward a more sustainable management and use of landscape resources. The proposed methodology has been applied in several real case studies to test its validity. In the present paper the Comunità Montana Alpi Lepontine (CMAL) case is outlined. In order to achieve the adhesion to the European Charter for Sustainable Tourism in Protected Areas, several stakeholders and public bodies, belonging to thirteen municipalities in Northern Italy have cooperated. The efforts to preserve and boost economy in such peculiarly landscape compel to cope with landscape different aspects - scientific, historical, artistic and economical - from a multidisciplinary holistic point of view. This approach enables a complex scientific image, as a driver, in order to suggest integrated and effective planning actions for a rational use of natural and cultural landscape resources. This also requires a stronger integration and improved sharing of information among such a number of local actors. This could be better performed thanks to the state of the art of information technologies such as the paradigm of Interconnected Geo Semantic Web Communities.
Published: 2008

37. Predictors of choice of initial antifungal treatment in intraabdominal candidiasis.

Author: Universitat Rovira i Virgili, Lagunes L, Borgatta B, Martín-Gomez MT, Rey-Pérez A, Antonelli M, Righi E, Merelli M, Brugnaro P, Dimopoulos G, Garnacho-Montero J, Colombo AL, Luzzati R, Menichetti F, Muñoz P, Nucci M, Scotton G, Viscoli C, Tumbarello M, Bassetti M, Rello J, IAC Study Investigators, Universitat Rovira i Virgili, and Lagunes L, Borgatta B, Martín-Gomez MT, Rey-Pérez A, Antonelli M, Righi E, Merelli M, Brugnaro P, Dimopoulos G, Garnacho-Montero J, Colombo AL, Luzzati R, Menichetti F, Muñoz P, Nucci M, Scotton G, Viscoli C, Tumbarello M, Bassetti M, Rello J, IAC Study Investigators
Abstract: Intraabdominal candidiasis (IAC) is the second most frequent form of invasive candidiasis, and is associated with high mortality rates. This study aims to identify current practices in initial antifungal treatment (IAT) in a real-world scenario and to define the predictors of the choice of echinocandins or azoles in IAC episodes. Secondary analysis was performed of a multinational retrospective cohort at 13 teaching hospitals in four countries (Italy, Greece, Spain and Brazil), over a 3-year period (2011-2013). IAC was identified in 481 patients, 323 of whom received antifungal therapy (classified as the treatment group). After excluding 13 patients given amphotericin B, the treatment group was further divided into the echinocandin group (209 patients; 64.7%) and the azole group (101 patients; 323%). Median APACHE II scores were significantly higher in the echinocandin group (p 0.013), but IAT did not differ significantly with regard to the Candida species involved. Logistic multivariate stepwise regression analysis, adjusted for centre effect, identified septic shock (adjusted OR (aOR) 1.54), APACHE II >15 (aOR 1.16) and presence in surgical ward at diagnosis (aOR 1.16) as the top three independent variables associated with an empirical echinocandin regimen. No differences in 30-day mortality were observed between groups. Echinocandin regimen was the first choice for IAT in patients with IAC. No statistical differences in mortality were observed between regimens, but echinocandins were administered to patients with more severe disease. Some disagreements were identified between current clinical guidelines and prescription of antifungals for IAC at the bedside, so further educational measures are required to optimize therapies. L. Lagunes, (C) 2016 European Society of C
Published: 2016

38. Predictors of choice of initial antifungal treatment in intraabdominal candidiasis

Author: Lagunes, L., Borgatta, B., Martín-Gomez, M. T., Rey-Pérez, A., Antonelli, M. (ORCID:0000-0003-3007-1670), Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, G., Garnacho-Montero, J., Colombo, A. L., Luzzati, R., Menichetti, F., Muñoz Tavira, P., Nucci, M., Scotton, G., Viscoli, C., Tumbarello, M. (ORCID:0000-0002-9519-8552), Bassetti, M., Rello, J., Ansaldi, F., Scarparo, C., Diaz-Martin, A., Palacios-Garcia, I., Rosin, C., Almirante, B., Baldin, G., Vena, A., Bouza, E., de Egea, V., Tascini, C., Tagliaferri, E., Sanguinetti, M. (ORCID:0000-0002-9780-7059), Mesini, A., Sganga, G. (ORCID:0000-0001-5079-0395), Busetti, M., Pumarola, T., Martin, M. T., Nouér, S. A., Pelaez, T., Raise, E., Grandesso, S., Del Bono, V., Esteves, P., Trucchi, C., Sartor, A., De Pascale, G., Posteraro, B. (ORCID:0000-0002-1663-7546), Lagunes, L., Borgatta, B., Martín-Gomez, M. T., Rey-Pérez, A., Antonelli, M. (ORCID:0000-0003-3007-1670), Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, G., Garnacho-Montero, J., Colombo, A. L., Luzzati, R., Menichetti, F., Muñoz Tavira, P., Nucci, M., Scotton, G., Viscoli, C., Tumbarello, M. (ORCID:0000-0002-9519-8552), Bassetti, M., Rello, J., Ansaldi, F., Scarparo, C., Diaz-Martin, A., Palacios-Garcia, I., Rosin, C., Almirante, B., Baldin, G., Vena, A., Bouza, E., de Egea, V., Tascini, C., Tagliaferri, E., Sanguinetti, M. (ORCID:0000-0002-9780-7059), Mesini, A., Sganga, G. (ORCID:0000-0001-5079-0395), Busetti, M., Pumarola, T., Martin, M. T., Nouér, S. A., Pelaez, T., Raise, E., Grandesso, S., Del Bono, V., Esteves, P., Trucchi, C., Sartor, A., De Pascale, G., and Posteraro, B. (ORCID:0000-0002-1663-7546)
Abstract: Intraabdominal candidiasis (IAC) is the second most frequent form of invasive candidiasis, and is associated with high mortality rates. This study aims to identify current practices in initial antifungal treatment (IAT) in a real-world scenario and to define the predictors of the choice of echinocandins or azoles in IAC episodes. Secondary analysis was performed of a multinational retrospective cohort at 13 teaching hospitals in four countries (Italy, Greece, Spain and Brazil), over a 3-year period (2011–2013). IAC was identified in 481 patients, 323 of whom received antifungal therapy (classified as the treatment group). After excluding 13 patients given amphotericin B, the treatment group was further divided into the echinocandin group (209 patients; 64.7%) and the azole group (101 patients; 32.3%). Median APACHE II scores were significantly higher in the echinocandin group (p 0.013), but IAT did not differ significantly with regard to the Candida species involved. Logistic multivariate stepwise regression analysis, adjusted for centre effect, identified septic shock (adjusted OR (aOR) 1.54), APACHE II >15 (aOR 1.16) and presence in surgical ward at diagnosis (aOR 1.16) as the top three independent variables associated with an empirical echinocandin regimen. No differences in 30-day mortality were observed between groups. Echinocandin regimen was the first choice for IAT in patients with IAC. No statistical differences in mortality were observed between regimens, but echinocandins were administered to patients with more severe disease. Some disagreements were identified between current clinical guidelines and prescription of antifungals for IAC at the bedside, so further educational measures are required to optimize therapies.
Published: 2016

39. Predictors of choice of initial antifungal treatment in intraabdominal candidiasis

Author: Pfizer, Merck Sharp & Dohme de España, Merck Serono, Astellas Pharma, MSD, Gilead Sciences, United Medical Corporation, Novartis, AstraZeneca, Zambon, Lagunes, L., Borgatta, B., Martín-Gómez, María Teresa, Rey-Pérez, A., Antonelli, Massimo, Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, George, Garnacho-Montero, José, Colombo, A. L., Luzzati, Roberto, Menichetti, F., Muñoz García, Patricia, Nucci, M., Scotton, G, Viscoli, C., Tumbarello, Mario, Bassetti, Matteo, Rello, J., Pfizer, Merck Sharp & Dohme de España, Merck Serono, Astellas Pharma, MSD, Gilead Sciences, United Medical Corporation, Novartis, AstraZeneca, Zambon, Lagunes, L., Borgatta, B., Martín-Gómez, María Teresa, Rey-Pérez, A., Antonelli, Massimo, Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, George, Garnacho-Montero, José, Colombo, A. L., Luzzati, Roberto, Menichetti, F., Muñoz García, Patricia, Nucci, M., Scotton, G, Viscoli, C., Tumbarello, Mario, Bassetti, Matteo, and Rello, J.
Abstract: Intraabdominal candidiasis (IAC) is the second most frequent form of invasive candidiasis, and is associated with high mortality rates. This study aims to identify current practices in initial antifungal treatment (IAT) in a real-world scenario and to define the predictors of the choice of echinocandins or azoles in IAC episodes. Secondary analysis was performed of a multinational retrospective cohort at 13 teaching hospitals in four countries (Italy, Greece, Spain and Brazil), over a 3-year period (2011–2013). IAC was identified in 481 patients, 323 of whom received antifungal therapy (classified as the treatment group). After excluding 13 patients given amphotericin B, the treatment group was further divided into the echinocandin group (209 patients; 64.7%) and the azole group (101 patients; 32.3%). Median APACHE II scores were significantly higher in the echinocandin group (p 0.013), but IAT did not differ significantly with regard to the Candida species involved. Logistic multivariate stepwise regression analysis, adjusted for centre effect, identified septic shock (adjusted OR (aOR) 1.54), APACHE II >15 (aOR 1.16) and presence in surgical ward at diagnosis (aOR 1.16) as the top three independent variables associated with an empirical echinocandin regimen. No differences in 30-day mortality were observed between groups. Echinocandin regimen was the first choice for IAT in patients with IAC. No statistical differences in mortality were observed between regimens, but echinocandins were administered to patients with more severe disease. Some disagreements were identified between current clinical guidelines and prescription of antifungals for IAC at the bedside, so further educational measures are required to optimize therapies.
Published: 2016

40. Predictors of choice of initial antifungal treatment in intraabdominal candidiasis

Author: Lagunes, L., Borgatta, B., Martín-Gomez, M. T., Rey-Pérez, A., Antonelli, Massimo, Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, G., Garnacho-Montero, J., Colombo, A. L., Luzzati, R., Menichetti, F., Muñoz Tavira, P., Nucci, M., Scotton, G., Viscoli, C., Tumbarello, Mario, Bassetti, M., Rello, J., Ansaldi, F., Scarparo, C., Diaz-Martin, A., Palacios-Garcia, I., Rosin, C., Almirante, B., Baldin, Gianmaria, Vena, A., Bouza, E., de Egea, V., Tascini, C., Tagliaferri, E., Sanguinetti, Maurizio, Mesini, A., Sganga, Gabriele, Busetti, M., Pumarola, T., Martin, M. T., Nouér, S. A., Pelaez, T., Raise, E., Grandesso, S., Del Bono, V., Esteves, P., Trucchi, C., Sartor, A., De Pascale, Gennaro, Posteraro, Brunella, Antonelli, M. (ORCID:0000-0003-3007-1670), Tumbarello, M. (ORCID:0000-0002-9519-8552), Baldin, G., Sanguinetti, M. (ORCID:0000-0002-9780-7059), Sganga, G. (ORCID:0000-0001-5079-0395), De Pascale, G. (ORCID:0000-0002-8255-0676), Posteraro, B. (ORCID:0000-0002-1663-7546), Lagunes, L., Borgatta, B., Martín-Gomez, M. T., Rey-Pérez, A., Antonelli, Massimo, Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, G., Garnacho-Montero, J., Colombo, A. L., Luzzati, R., Menichetti, F., Muñoz Tavira, P., Nucci, M., Scotton, G., Viscoli, C., Tumbarello, Mario, Bassetti, M., Rello, J., Ansaldi, F., Scarparo, C., Diaz-Martin, A., Palacios-Garcia, I., Rosin, C., Almirante, B., Baldin, Gianmaria, Vena, A., Bouza, E., de Egea, V., Tascini, C., Tagliaferri, E., Sanguinetti, Maurizio, Mesini, A., Sganga, Gabriele, Busetti, M., Pumarola, T., Martin, M. T., Nouér, S. A., Pelaez, T., Raise, E., Grandesso, S., Del Bono, V., Esteves, P., Trucchi, C., Sartor, A., De Pascale, Gennaro, Posteraro, Brunella, Antonelli, M. (ORCID:0000-0003-3007-1670), Tumbarello, M. (ORCID:0000-0002-9519-8552), Baldin, G., Sanguinetti, M. (ORCID:0000-0002-9780-7059), Sganga, G. (ORCID:0000-0001-5079-0395), De Pascale, G. (ORCID:0000-0002-8255-0676), and Posteraro, B. (ORCID:0000-0002-1663-7546)
Abstract: Intraabdominal candidiasis (IAC) is the second most frequent form of invasive candidiasis, and is associated with high mortality rates. This study aims to identify current practices in initial antifungal treatment (IAT) in a real-world scenario and to define the predictors of the choice of echinocandins or azoles in IAC episodes. Secondary analysis was performed of a multinational retrospective cohort at 13 teaching hospitals in four countries (Italy, Greece, Spain and Brazil), over a 3-year period (2011–2013). IAC was identified in 481 patients, 323 of whom received antifungal therapy (classified as the treatment group). After excluding 13 patients given amphotericin B, the treatment group was further divided into the echinocandin group (209 patients; 64.7%) and the azole group (101 patients; 32.3%). Median APACHE II scores were significantly higher in the echinocandin group (p 0.013), but IAT did not differ significantly with regard to the Candida species involved. Logistic multivariate stepwise regression analysis, adjusted for centre effect, identified septic shock (adjusted OR (aOR) 1.54), APACHE II >15 (aOR 1.16) and presence in surgical ward at diagnosis (aOR 1.16) as the top three independent variables associated with an empirical echinocandin regimen. No differences in 30-day mortality were observed between groups. Echinocandin regimen was the first choice for IAT in patients with IAC. No statistical differences in mortality were observed between regimens, but echinocandins were administered to patients with more severe disease. Some disagreements were identified between current clinical guidelines and prescription of antifungals for IAC at the bedside, so further educational measures are required to optimize therapies.
Published: 2016

41. Predictors of choice of initial antifungal treatment in intraabdominal candidiasis

Author: Lagunes, L, Borgatta, B, Martín Gomez, M. T, Rey Pérez, A, Antonelli, Massimo, Righi, E, Merelli, M, Brugnaro, P, Dimopoulos, G, Garnacho Montero, J, Colombo, A. L, Luzzati, R, Menichetti, F, Muñoz, P, Nucci, M, Scotton, G, Viscoli, C, Tumbarello, Mario, Bassetti, M, Rello, J., Antonelli, Massimo (ORCID:0000-0003-3007-1670), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Lagunes, L, Borgatta, B, Martín Gomez, M. T, Rey Pérez, A, Antonelli, Massimo, Righi, E, Merelli, M, Brugnaro, P, Dimopoulos, G, Garnacho Montero, J, Colombo, A. L, Luzzati, R, Menichetti, F, Muñoz, P, Nucci, M, Scotton, G, Viscoli, C, Tumbarello, Mario, Bassetti, M, Rello, J., Antonelli, Massimo (ORCID:0000-0003-3007-1670), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)
Abstract: Intraabdominal candidiasis (IAC) is the second most frequent form of invasive candidiasis, and is associated with high mortality rates. This study aims to identify current practices in initial antifungal treatment (IAT) in a real-world scenario and to define the predictors of the choice of echinocandins or azoles in IAC episodes. Secondary analysis was performed of a multinational retrospective cohort at 13 teaching hospitals in four countries (Italy, Greece, Spain and Brazil), over a 3-year period (2011-2013). IAC was identified in 481 patients, 323 of whom received antifungal therapy (classified as the treatment group). After excluding 13 patients given amphotericin B, the treatment group was further divided into the echinocandin group (209 patients; 64.7%) and the azole group (101 patients; 32.3%). Median APACHE II scores were significantly higher in the echinocandin group (p 0.013), but IAT did not differ significantly with regard to the Candida species involved. Logistic multivariate stepwise regression analysis, adjusted for centre effect, identified septic shock (adjusted OR (aOR) 1.54), APACHE II >15 (aOR 1.16) and presence in surgical ward at diagnosis (aOR 1.16) as the top three independent variables associated with an empirical echinocandin regimen. No differences in 30-day mortality were observed between groups. Echinocandin regimen was the first choice for IAT in patients with IAC. No statistical differences in mortality were observed between regimens, but echinocandins were administered to patients with more severe disease. Some disagreements were identified between current clinical guidelines and prescription of antifungals for IAC at the bedside, so further educational measures are required to optimize therapies.
Published: 2016

42. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.

Author: Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., Verweij, P.E., Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., and Verweij, P.E.
Abstract: Contains fulltext : 153751.pdf (publisher's version ) (Open Access)
Published: 2015

43. $s$-Processing in AGB Stars Revisited. II. Enhanced $^{13}$C Production Through MHD-Induced Mixing

Author: Trippella, O., Busso, M., Palmerini, S., Maiorca, E., Nucci, M. C., Trippella, O., Busso, M., Palmerini, S., Maiorca, E., and Nucci, M. C.
Abstract: Slow neutron captures are responsible for the production of about $50\%$ of elements heavier than iron, mainly, occurring during the asymptotic giant branch phase of low-mass stars ($1$ $\lesssim M$/M$_{\odot}$ $\lesssim$ $3$), where the main neutron source is the $^{13}$C($\alpha$,n)$^{16}$O reaction. This last is activated from locally-produced $^{13}$C, formed by partial mixing of hydrogen into the He-rich layers. We present here the first attempt at describing a physical mechanism for the formation of the $^{13}$C reservoir, studying the mass circulation induced by magnetic buoyancy and without adding new free parameters to those already involved in stellar modelling. Our approach represents the application, to the stellar layers relevant for $s$-processing, of recent exact, analytical 2D and 3D models for magneto-hydrodynamic processes at the base of convective envelopes in evolved stars in order to promote downflows of envelope material for mass conservation, during the occurrence of a dredge-up phenomenon. We find that the proton penetration is characterized by small concentrations, but extended over a large fractional mass of the He-layers, thus producing $^{13}$C reservoirs of several $10^{-3}$ M$_{\odot}$. The ensuing $^{13}$C-enriched zone has an almost flat profile, while only a limited production of $^{14}$N occurs. In order to verify the effects of our new findings we show how the abundances of the main $s$-component nuclei can be accounted for in solar proportions and how our large $^{13}$C-reservoir allows us to solve a few so far unexplained features in the abundance distribution of post-AGB objects.
Published: 2015
Full Text: View/download PDF

44. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.

Author: Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., Verweij, P.E., Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., and Verweij, P.E.
Abstract: Contains fulltext : 153751.pdf (publisher's version ) (Open Access)
Published: 2015

45. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.

Author: Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., Verweij, P.E., Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., and Verweij, P.E.
Abstract: Contains fulltext : 153751.pdf (publisher's version ) (Open Access)
Published: 2015

46. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality

Author: Bassetti, M, Righi, E, Ansaldi, F, Merelli, M, Scarparo, C, Antonelli, Massimo, Garnacho Montero, J, Diaz Martin, A, Palacios Garcia, I, Luzzati, R, Rosin, C, Lagunes, L, Rello, J, Almirante, B, Scotton, Pg, Baldin, G, Dimopoulos, G, Nucci, M, Munoz, P, Vena, A, Bouza, E, De Egea, V, Colombo, Al, Tascini, C, Menichetti, F, Tagliaferri, E, Brugnaro, P, Sanguinetti, Maurizio, Mesini, A, Sganga, Gabriele, Viscoli, C, Tumbarello, Mario, Antonelli, Massimo (ORCID:0000-0003-3007-1670), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Sganga, Gabriele (ORCID:0000-0001-5079-0395), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Bassetti, M, Righi, E, Ansaldi, F, Merelli, M, Scarparo, C, Antonelli, Massimo, Garnacho Montero, J, Diaz Martin, A, Palacios Garcia, I, Luzzati, R, Rosin, C, Lagunes, L, Rello, J, Almirante, B, Scotton, Pg, Baldin, G, Dimopoulos, G, Nucci, M, Munoz, P, Vena, A, Bouza, E, De Egea, V, Colombo, Al, Tascini, C, Menichetti, F, Tagliaferri, E, Brugnaro, P, Sanguinetti, Maurizio, Mesini, A, Sganga, Gabriele, Viscoli, C, Tumbarello, Mario, Antonelli, Massimo (ORCID:0000-0003-3007-1670), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Sganga, Gabriele (ORCID:0000-0001-5079-0395), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)
Abstract: Clinical data on patients with intra-abdominal candidiasis (IAC) is still scarce.
Published: 2015

47. $s$-Processing in AGB Stars Revisited. II. Enhanced $^{13}$C Production Through MHD-Induced Mixing

Author: Trippella, O., Busso, M., Palmerini, S., Maiorca, E., Nucci, M. C., Trippella, O., Busso, M., Palmerini, S., Maiorca, E., and Nucci, M. C.
Abstract: Slow neutron captures are responsible for the production of about $50\%$ of elements heavier than iron, mainly, occurring during the asymptotic giant branch phase of low-mass stars ($1$ $\lesssim M$/M$_{\odot}$ $\lesssim$ $3$), where the main neutron source is the $^{13}$C($\alpha$,n)$^{16}$O reaction. This last is activated from locally-produced $^{13}$C, formed by partial mixing of hydrogen into the He-rich layers. We present here the first attempt at describing a physical mechanism for the formation of the $^{13}$C reservoir, studying the mass circulation induced by magnetic buoyancy and without adding new free parameters to those already involved in stellar modelling. Our approach represents the application, to the stellar layers relevant for $s$-processing, of recent exact, analytical 2D and 3D models for magneto-hydrodynamic processes at the base of convective envelopes in evolved stars in order to promote downflows of envelope material for mass conservation, during the occurrence of a dredge-up phenomenon. We find that the proton penetration is characterized by small concentrations, but extended over a large fractional mass of the He-layers, thus producing $^{13}$C reservoirs of several $10^{-3}$ M$_{\odot}$. The ensuing $^{13}$C-enriched zone has an almost flat profile, while only a limited production of $^{14}$N occurs. In order to verify the effects of our new findings we show how the abundances of the main $s$-component nuclei can be accounted for in solar proportions and how our large $^{13}$C-reservoir allows us to solve a few so far unexplained features in the abundance distribution of post-AGB objects.
Published: 2015
Full Text: View/download PDF

48. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality

Author: Bassetti, M, Righi, E, Ansaldi, F, Merelli, M, Scarparo, C, Antonelli, Massimo, Garnacho Montero, J, Diaz Martin, A, Palacios Garcia, I, Luzzati, R, Rosin, C, Lagunes, L, Rello, J, Almirante, B, Scotton, Pg, Baldin, G, Dimopoulos, G, Nucci, M, Munoz, P, Vena, A, Bouza, E, De Egea, V, Colombo, Al, Tascini, C, Menichetti, F, Tagliaferri, E, Brugnaro, P, Sanguinetti, Maurizio, Mesini, A, Sganga, Gabriele, Viscoli, C, Tumbarello, Mario, Antonelli, Massimo (ORCID:0000-0003-3007-1670), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Sganga, Gabriele (ORCID:0000-0001-5079-0395), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Bassetti, M, Righi, E, Ansaldi, F, Merelli, M, Scarparo, C, Antonelli, Massimo, Garnacho Montero, J, Diaz Martin, A, Palacios Garcia, I, Luzzati, R, Rosin, C, Lagunes, L, Rello, J, Almirante, B, Scotton, Pg, Baldin, G, Dimopoulos, G, Nucci, M, Munoz, P, Vena, A, Bouza, E, De Egea, V, Colombo, Al, Tascini, C, Menichetti, F, Tagliaferri, E, Brugnaro, P, Sanguinetti, Maurizio, Mesini, A, Sganga, Gabriele, Viscoli, C, Tumbarello, Mario, Antonelli, Massimo (ORCID:0000-0003-3007-1670), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Sganga, Gabriele (ORCID:0000-0001-5079-0395), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)
Abstract: Purpose: Clinical data on patients with intra-abdominal candidiasis (IAC) is still scarce. Methods: We collected data from 13 hospitals in Italy, Spain, Brazil, and Greece over a 3-year period (2011–2013) including patients from ICU, medical, and surgical wards. Results: A total of 481 patients were included in the study. Of these, 27 % were hospitalized in ICU. Mean age was 63 years and 57 % of patients were male. IAC mainly consisted of secondary peritonitis (41 %) and abdominal abscesses (30 %); 68 (14 %) cases were also candidemic and 331 (69 %) had concomitant bacterial infections. The most commonly isolated Candida species were C. albicans (n = 308 isolates, 64 %) and C. glabrata (n = 76, 16 %). Antifungal treatment included echinocandins (64 %), azoles (32 %), and amphotericin B (4 %). Septic shock was documented in 40.5 % of patients. Overall 30-day hospital mortality was 27 % with 38.9 % mortality in ICU. Multivariate logistic regression showed that age (OR 1.05, 95 % CI 1.03–1.07, P\0.001), increments in 1-point APACHE II scores (OR 1.05, 95 % CI 1.01–1.08, P = 0.028), secondary peritonitis (OR 1.72, 95 % CI 1.02–2.89, P = 0.019), septic shock (OR 3.29, 95 % CI 1.88–5.86, P\0.001), and absence of adequate abdominal source control (OR 3.35, 95 % CI 2.01–5.63, P\0.001) were associated with mortality. In patients with septic shock, absence of source control correlated with mortality rates above 60 % irrespective of administration of an adequate antifungal therapy. Conclusions: Low percentages of concomitant candidemia and high mortality rates are documented in IAC. In patients presenting with septic shock, source control is fundamental
Published: 2015

49. MHD and deep mixing in evolved stars. 1. 2D and 3D analytical models for the AGB

Author: Nucci, M. C., Busso, M., Nucci, M. C., and Busso, M.
Abstract: The advection of thermonuclear ashes by magnetized domains emerging from near the H-shell was suggested to explain AGB star abundances. Here we verify this idea quantitatively through exact MHD models. Starting with a simple 2D geometry and in an inertia frame, we study plasma equilibria avoiding the complications of numerical simulations. We show that, below the convective envelope of an AGB star, variable magnetic fields induce a natural expansion, permitted by the almost ideal MHD conditions, in which the radial velocity grows as the second power of the radius. We then study the convective envelope, where the complexity of macro-turbulence allows only for a schematic analytical treatment. Here the radial velocity depends on the square root of the radius. We then verify the robustness of our results with 3D calculations for the velocity, showing that, for both the studied regions, the solution previously found can be seen as a planar section of a more complex behavior, in which anyway the average radial velocity retains the same dependency on radius found in 2D. As a final check, we compare our results to approximate descriptions of buoyant magnetic structures. For realistic boundary conditions the envelope crossing times are sufficient to disperse in the huge convective zone any material transported, suggesting magnetic advection as a promising mechanism for deep mixing. The mixing velocities are smaller than for convection, but larger than for diffusion and adequate to extra-mixing in red giants.
Published: 2014
Full Text: View/download PDF

50. Improvement in the outcome of invasive fusariosis in the last decade

Author: Nucci, M., Marr, K. A., Vehreschild, M. J. G. T., de Souza, C. A., Velasco, E., Cappellano, P., Carlesse, F., Queiroz-Telles, F., Sheppard, D. C., Kindo, A., Cesaro, S., Hamerschlak, N., Solza, C., Heinz, W. J., Schaller, M., Atalla, A., Arikan-Akdagli, S., Bertz, H., Castro, C. Galvao, Jr., Herbrecht, R., Hoenigl, M., Haerter, G., Hermansen, N. E. U., Josting, A., Pagano, L., Salles, M. J. C., Mossad, S. B., Ogunc, D., Pasqualotto, A. C., Araujo, V., Troke, P. F., Lortholary, O., Cornely, O. A., Anaissie, E., Nucci, M., Marr, K. A., Vehreschild, M. J. G. T., de Souza, C. A., Velasco, E., Cappellano, P., Carlesse, F., Queiroz-Telles, F., Sheppard, D. C., Kindo, A., Cesaro, S., Hamerschlak, N., Solza, C., Heinz, W. J., Schaller, M., Atalla, A., Arikan-Akdagli, S., Bertz, H., Castro, C. Galvao, Jr., Herbrecht, R., Hoenigl, M., Haerter, G., Hermansen, N. E. U., Josting, A., Pagano, L., Salles, M. J. C., Mossad, S. B., Ogunc, D., Pasqualotto, A. C., Araujo, V., Troke, P. F., Lortholary, O., Cornely, O. A., and Anaissie, E.
Abstract: Invasive fusariosis (IF) has been associated with a poor prognosis. Although recent series have reported improved outcomes, the definition of optimal treatments remains controversial. The objective of this study was to evaluate changes in the outcome of IF. Weretrospectively analysed 233 cases of IF from 11 countries, comparing demographics, clinical findings, treatment and outcome in two periods: 1985-2000 (period 1) and 2001-2011 (period 2). Most patients (92%) had haematological disease. Primary treatment with deoxycholate amphotericin B was more frequent in period 1 (63% vs. 30%, p <0.001), whereas voriconazole (32% vs. 2%, p <0.001) and combination therapies (18% vs. 1%, p <0.001) were more frequent in period 2. The 90-day probabilities of survival in periods 1 and 2 were 22% and 43%, respectively (p <0.001). In period 2, the 90-day probabilities of survival were 60% with voriconazole, 53% with a lipid formulation of amphotericin B, and 28% with deoxycholate amphotericin B (p 0.04). Variables associated with poor prognosis (death 90 days after the diagnosis of fusariosis) by multivariable analysis were: receipt of corticosteroids (hazard ratio (HR) 2.11, 95% CI 1.18-3.76, p 0.01), neutropenia at end of treatment (HR 2.70, 95% CI 1.57-4.65, p <0.001), and receipt of deoxycholate amphotericin B (HR 1.83, 95% CI 1.06-3.16, p 0.03). Treatment practices have changed over the last decade, with an increased use of voriconazole and combination therapies. There has been a 21% increase in survival rate in the last decade.
Published: 2014

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Journal

Database

Publisher

66 results on '"Nucci, M."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources